<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treatment for telangiectasias and reticular veins - Nakano, LCU - 2021 | Cochrane Library</title> <meta content="Treatment for telangiectasias and reticular veins - Nakano, LCU - 2021 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012723.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treatment for telangiectasias and reticular veins - Nakano, LCU - 2021 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012723.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012723.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Treatment for telangiectasias and reticular veins" name="citation_title"/> <meta content="Luis CU Nakano" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="luiscnakano@uol.com.br" name="citation_author_email"/> <meta content="Daniel G Cacione" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Jose CC Baptista-Silva" name="citation_author"/> <meta content="Ronald LG Flumignan" name="citation_author"/> <meta content="Universidade Federal de São Paulo" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD012723.pub2" name="citation_doi"/> <meta content="2021" name="citation_date"/> <meta content="2021/10/12" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012723.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012723.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012723.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Pruritus [drug therapy]; Sclerotherapy; *Telangiectasis [therapy]; *Veins" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012723.pub2&amp;doi=10.1002/14651858.CD012723.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012723\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012723\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ms","hr","fa","fr","hu"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012723.pub2",title:"Treatment for telangiectasias and reticular veins",firstPublishedDate:"Oct 12, 2021 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Vascular Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012723.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012723.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012723.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012723.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012723.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012723.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;hu&quot;,&quot;title&quot;:&quot;Összefoglalás közérthető nyelven&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012723.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012723.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012723.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012723.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4265 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012723.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0130"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0039"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-sec-0114"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/appendices#CD012723-sec-0135"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/supinfo/CD012723StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/supinfo/CD012723StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2021 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treatment for telangiectasias and reticular veins</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#CD012723-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Luis CU Nakano</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#CD012723-cr-0005">Daniel G Cacione</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#CD012723-cr-0006">Jose CC Baptista-Silva</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information#CD012723-cr-0007">Ronald LG Flumignan</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information/en#CD012723-sec-0141">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 12 October 2021 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012723.pub2">https://doi.org/10.1002/14651858.CD012723.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012723-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012723-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012723-abs-0013">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012723-abs-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012723-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012723-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012723-abs-0001" lang="en"> <section id="CD012723-sec-0001"> <h3 class="title" id="CD012723-sec-0001">Background</h3> <p>Telangiectasias (spider veins) and reticular veins on the lower limbs are very common, increase with age, and have been found in 41% of women. The cause is unknown and the patients may be asymptomatic or can report pain, burning or itching. Treatments include sclerotherapy, laser, intense pulsed light, microphlebectomy and thermoablation, but none is established as preferable. </p> </section> <section id="CD012723-sec-0002"> <h3 class="title" id="CD012723-sec-0002">Objectives</h3> <p>To assess the effects of sclerotherapy, laser therapy, intensive pulsed light, thermocoagulation, and microphlebectomy treatments for telangiectasias and reticular veins. </p> </section> <section id="CD012723-sec-0003"> <h3 class="title" id="CD012723-sec-0003">Search methods</h3> <p>The Cochrane Vascular Information Specialist searched the Cochrane Vascular Specialised Register, CENTRAL, MEDLINE, Embase, AMED and CINAHL databases, and the World Health Organization International Clinical Trials Registry Platform and ClinicalTrials.gov trials registers to 16 March 2021. We undertook additional searches in LILACS and IBECS databases, reference checking, and contacted specialists in the field, manufacturers and study authors to identify additional studies. </p> </section> <section id="CD012723-sec-0004"> <h3 class="title" id="CD012723-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) and quasi‐RCTs that compared treatment methods such as sclerotherapy, laser therapy, intensive pulsed light, thermocoagulation, and microphlebectomy for telangiectasias and reticular veins in the lower limb. We included studies that compared individual treatment methods against placebo, or that compared different sclerosing agents, foam or laser treatment, or that used a combination of treatment methods. </p> </section> <section id="CD012723-sec-0005"> <h3 class="title" id="CD012723-sec-0005">Data collection and analysis</h3> <p>Three review authors independently performed study selection, extracted data, assessed risks of bias and assessed the certainty of evidence using GRADE. The outcomes of interest were resolution or improvement (or both) of telangiectasias, adverse events (including hyperpigmentation, matting), pain, recurrence, time to resolution, and quality of life. </p> </section> <section id="CD012723-sec-0006"> <h3 class="title" id="CD012723-sec-0006">Main results</h3> <p>We included 3632 participants from 35 RCTs. Studies compared a variety of sclerosing agents, laser treatment and compression. No studies investigated intensive pulsed light, thermocoagulation or microphlebectomy. None of the included studies assessed recurrence or time to resolution. Overall the risk of bias of the included studies was moderate. We downgraded the certainty of evidence to moderate or low because of clinical heterogeneity and imprecision due to the wide confidence intervals (CIs) and few participants for each comparison. </p> <p><b>Any sclerosing agent versus placebo</b> </p> <p>There was moderate‐certainty evidence that sclerosing agents showed more resolution or improvement of telangiectasias compared to placebo (standard mean difference (SMD) 3.08, 95% CI 2.68 to 3.48; 4 studies, 613 participants/procedures), and more frequent adverse events: hyperpigmentation (risk ratio (RR) 11.88, 95% CI 4.54 to 31.09; 3 studies, 528 participants/procedures); matting (RR 4.06, 95% CI 1.28 to 12.84; 3 studies, 528 participants/procedures). There may be more pain experienced in the sclerosing‐agents group compared to placebo (SMD 0.70, 95% CI 0.06 to 1.34; 1 study, 40 participants; low‐certainty evidence). </p> <p><b>Polidocanol versus any sclerosing agent</b> </p> <p>There was no clear difference in resolution or improvement (or both) of telangiectasias (SMD 0.01, 95% CI −0.13 to 0.14; 7 studies, 852 participants/procedures), hyperpigmentation (RR 0.94, 95% CI 0.62 to 1.43; 6 studies, 819 participants/procedures), or matting (RR 0.82, 95% CI 0.52 to 1.27; 7 studies, 859 participants/procedures), but there were fewer cases of pain (SMD −0.26, 95% CI −0.44 to −0.08; 5 studies, 480 participants/procedures) in the polidocanol group. All moderate‐certainty evidence. </p> <p><b>Sodium tetradecyl sulphate (STS) versus any sclerosing agent</b> </p> <p>There was no clear difference in resolution or improvement (or both) of telangiectasias (SMD −0.07, 95% CI −0.25 to 0.11; 4 studies, 473 participants/procedures). There was more hyperpigmentation (RR 1.71, 95% CI 1.10 to 2.64; 4 studies, 478 participants/procedures), matting (RR 2.10, 95% CI 1.14 to 3.85; 2 studies, 323 participants/procedures) and probably more pain (RR 1.49, 95% CI 0.99 to 2.25; 4 studies, 409 participants/procedures). All moderate‐certainty evidence. </p> <p><b>Foam versus any sclerosing agent</b> </p> <p>There was no clear difference in resolution or improvement (or both) of telangiectasias (SMD 0.04, 95% CI −0.26 to 0.34; 2 studies, 187 participants/procedures); hyperpigmentation (RR 2.12, 95% CI 0.44 to 10.23; 2 studies, 187 participants/procedures) or pain (SMD −0.10, 95% CI −0.44 to 0.24; 1 study, 147 participants/procedures). There may be more matting using foam (RR 6.12, 95% CI 1.04 to 35.98; 2 studies, 187 participants/procedures). All low‐certainty evidence. </p> <p><b>Laser versus any sclerosing agent</b> </p> <p>There was no clear difference in resolution or improvement (or both) of telangiectasias (SMD −0.09, 95% CI −0.25 to 0.07; 5 studies, 593 participants/procedures), or matting (RR 1.00, 95% CI 0.46 to 2.19; 2 studies, 162 participants/procedures), and maybe less hyperpigmentation (RR 0.57, 95% CI 0.40 to 0.80; 4 studies, 262 participants/procedures) in the laser group. All moderate‐certainty evidence. High heterogeneity of the studies reporting on pain prevented pooling, and results were inconsistent (low‐certainty evidence). </p> <p><b>Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol)</b> </p> <p>Low‐certainty evidence suggests there may be more resolution or improvement (or both) of telangiectasias in the combined group (SMD 5.68, 95% CI 5.14 to 6.23; 2 studies, 710 participants), and no clear difference in hyperpigmentation (RR 0.83, 95% CI 0.35 to 1.99; 2 studies, 656 participants) or matting (RR 0.83, 95% CI 0.21 to 3.28; 2 studies, 656 participants). There may be more pain in the combined group (RR 2.44, 95% CI 1.69 to 3.55; 1 study, 596 participants; low‐certainty evidence). </p> </section> <section id="CD012723-sec-0007"> <h3 class="title" id="CD012723-sec-0007">Authors' conclusions</h3> <p>Small numbers of studies and participants in each comparison limited our confidence in the evidence. Sclerosing agents were more effective than placebo for resolution or improvement of telangiectasias but also caused more adverse events (moderate‐certainty evidence), and may result in more pain (low‐certainty evidence). There was no evidence of a benefit in resolution or improvement for any sclerosant compared to another or to laser. There may be more resolution or improvement of telangiectasias in the combined laser and polidocanol group compared to polidocanol alone (low‐certainty evidence). There may be differences between treatments in adverse events and pain. Compared to other sclerosing agents polidocanol probably causes less pain; STS resulted in more hyperpigmentation, matting and probably pain; foam may cause more matting (low‐certainty evidence); laser treatment may result in less hyperpigmentation (moderate‐certainty evidence). Further well‐designed studies are required to provide evidence for other available treatments and important outcomes (such as recurrence, time to resolution and delayed adverse events); and to improve our confidence in the identified comparisons. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012723-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012723-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD012723-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012723-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012723-abs-0011">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD012723-abs-0007">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/hu#CD012723-abs-0012">Magyar</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012723-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012723-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012723-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012723-abs-0002" lang="en"> <h3>Treatment for telangiectasias and reticular veins</h3> <p><b>What are telangiectasias and reticular veins?</b> </p> <p>Telangiectasias (spider veins) are small dilated blood vessels near the skin surface measuring less than 1.0 mm in diameter. Reticular veins have a diameter of less than 3.0 mm and are deeper in the skin. The cause is unknown, and they can be solely cosmetic, or can result in pain, burning or itching. Telangiectasias and reticular veins on the legs are very common, increase with age, and have been found in 41% of women over the age of 50 years. Risk factors include family history, pregnancy, local trauma, obesity and hormonal factors </p> <p><b>How are telangiectasias and reticular veins treated?</b> </p> <p>There are several treatments, such as sclerotherapy, laser, intense pulsed light, microphlebectomy and thermoablation, but none is established as preferable. Unwanted side effects of treatments include hyperpigmentation (skin darkening), matting (new telangiectasis after treatment), allergy and pain. It is therefore important to know the effects of these treatments to help doctors and patients decide which is the best option for them. </p> <p><b>What did we do?</b> </p> <p>We searched for studies where patients were randomly selected to receive one treatment for spider veins compared to a sham treatment, or to another type of treatment. We then compared the results and summarised the evidence from all the studies. Finally, we assessed how certain we are of the evidence. We considered factors such as the way studies were conducted, study sizes, and consistency of findings across studies. Based on our assessments, we categorised the evidence as being of very low, low, moderate or high certainty. </p> <p><b>What did we find?</b> </p> <p>We found 35 studies with a combined total of 3632 participants (searched to 16 March 2021). Some studies compared one treatment on one leg to another treatment on the other leg. Studies used a variety of different treatments and none of them reported on all of our outcomes. Not all available treatments were investigated: no studies investigated intensive pulsed light, thermocoagulation or microphlebectomy. </p> <p>Sclerosing agents improved telangiectasias and reticular veins resolution when compared to sham treatment, but resulted in more unwanted side effects (hyperpigmentation and matting). There was no benefit seen in one sclerosing agent compared to another, or compared to laser, for improving telangiectasias. There may be differences between treatments in adverse events and pain. Compared to other agents, polidocanol may result in less pain. Sodium tetradecyl sulphate (STS) may cause more hyperpigmentation, matting and probably more pain; foam may result in more matting; laser treatment may cause less hyperpigmentation. Combined laser plus sclerotherapy may result in better resolution compared to only sclerotherapy, but may cause more pain. </p> <p><b>How reliable are these results?</b> </p> <p>We are not very confident in these results. We downgraded the certainty of the evidence by one or two levels (from high to moderate or low). This was because of the differences in the designs of the studies, which meant that only small numbers of studies and participants provided information for each treatment comparison. </p> <p><b>Conclusion</b> </p> <p>Further well‐designed studies are needed to improve our confidence in the comparisons identified in this review, for other treatments available, and for other important outcomes, such as recurrence, time to resolution and long‐term side effects. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012723-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012723-sec-0130"></div> <h3 class="title" id="CD012723-sec-0131">Implications for practice</h3> <section id="CD012723-sec-0131"> <p>Sclerosing agents were more effective than placebo for resolution or improvement of telangiectasias, but also cause more adverse events and pain (moderate and low‐certainty evidence). There was no evidence that any sclerosing agent resulted in more resolution or improvement of telangiectasias compared to another or to laser, but there may be some differences in adverse events and pain between some treatments: polidocanol probably causes less necrosis; hypertonic saline probably causes less hyperpigmentation but more pain compared to other sclerosing agents (moderate‐certainty evidence); STS resulted in more hyperpigmentation, matting and probably more pain than other sclerosing agents (moderate‐certainty evidence). Foam agents compared to liquid did not improve resolution, but there may be more matting (moderate‐certainty evidence). Laser treatment may result in less hyperpigmentation compared to any sclerosing agents (moderate‐certainty evidence); combining laser with polidocanol may be more effective to treat telangiectasias and reticular veins compared to polidocanol alone (low‐certainty evidence), but more pain may occur (low‐certainty evidence). There was more improvement of telangiectasias in combining polidocanol with hypertonic glucose compared with hypertonic glucose alone (moderate‐certainty evidence), and no clear differences in adverse events or pain (moderate‐certainty evidence). There was no clear difference in improvement, adverse events or quality of life when comparing sclerotherapy plus compression with sclerotherapy alone. Small numbers of studies and participants in each comparison limited our confidence in the evidence. </p> </section> <h3 class="title" id="CD012723-sec-0132">Implications for research</h3> <section id="CD012723-sec-0132"> <p>Although the treatment of telangiectasias and reticular veins has been conducted by vascular surgeons for several years, there is limited high‐certainty evidence. The lack of standardisation in studies also makes it difficult to analyse and summarise the evidence. We suggest that future trials use a standard methodology. For the intervention standard, the number of sessions is critical for access and to compare data. As most trials evaluated only one intervention session, we suggest that it should be standardised as a unique session to facilitate analysis of the outcome. </p> <p>Another important topic is the design of the study: some authors compared different individuals and others compare similar regions on different limbs in the same participant. In our view the best design for the study of telangiectasias and reticular veins is the split‐body design, since we are analysing different treatments in the same individual, and the response obtained can be inferred more appropriately for each treatment; we acknowledge that a split‐body design could aggravate the randomisation process. Different study designs can be considered, provided that they are well‐standardised and specified. </p> <p>We suggest using a single scale to facilitate the interpretation of results for the 'improvement or resolution' outcome and later inclusion of studies in a meta‐analysis. Most of the reviewed studies used a scale of 0 to 4, so we suggest the use of this scale in future trials, with specifications in percentages in order to infer the results obtained with more precision. </p> <p>When evaluating adverse events it is important for future studies to establish whether they are immediate or late effects. We suggest that immediate adverse events should be evaluated just after the specific session and delayed adverse events arising three to six months after the procedure should also be evaluated in order to study their evolution. </p> <p>In the studies reviewed here, pain was analysed using the analogue pain scale (0 to 100 mm), and we suggest that standardising the VAS for pain is important for the comparison of results. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012723-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012723-sec-0008"></div> <div class="table" id="CD012723-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (any)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures*<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 3.08 higher<br/>(2.68 higher to 3.48 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>613<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.88<br/>(4.54 to 31.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>528<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1000<br/>(114 to 784) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.06<br/>(1.28 to 12.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>528<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(22 to 216) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.7 higher<br/>(0.06 higher to 1.34 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Three studies used participants as the unit of analysis and one study used the number of procedures as the unit of analysis for each comparison. <br/><sup>a</sup>We downgraded by one level due to high clinical heterogeneity of the included studies.<br/><sup>b</sup>We downgraded by one level due to high clinical heterogeneity of the included studies and wide CI of the included studies (imprecision).<br/><sup>c</sup> We downgraded by two levels due to high clinical heterogeneity of the included studies and only one included study with few participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (polidocanol)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosant agent)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (polidocanol)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.01 higher<br/>(0.13 lower to 0.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>852<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.62 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>819<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000<br/>(295 to 680) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.52 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>859<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/>(75 to 183) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.26 lower<br/>(0.44 lower to 0.08 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Three studies used participants as the unit of analysis and four studies used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by one level due to wide CIs. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (STS)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosant)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (STS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.07 lower<br/>(0.25 lower to 0.11 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/>(1.10 to 2.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>478<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>634 per 1000<br/>(408 to 979) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.10<br/>(1.14 to 3.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>323<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/>(94 to 318) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.49<br/>(0.99 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>409<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>410 per 1000<br/>(273 to 619) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Two studies used participants as the unit of analysis and four studies used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by one level due to wide CIs and small number of participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0004"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (hypertonic saline)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosant)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (hypertonic saline)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.01 higher<br/>(0.2 lower to 0.22 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 8 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.59 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>365 per 1000<br/>(291 to 459) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 8 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.58 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/>(125 to 293) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 6.22 higher<br/>(5.7 higher to 6.73 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD</b>: standard mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> All studies used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by one level because of high risk of other bias in the included studies.<br/><sup>b</sup>We downgraded by one level because of wide CIs.<br/><sup>c</sup>We downgraded by one level because of clinical heterogeneity between included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0005"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (chromated glycerin)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosing agent)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (chromated glycerin)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 5 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.45 higher<br/>(0.11 lower to 1.02 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 5 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.49<br/>(0.09 to 2.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/>(6 to 164) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 5 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.31<br/>(0.01 to 7.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(0 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50</p> <p>(0.30 to 7.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000<br/>(46 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> One study used participants as the unit of analysis and one study used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup> We downgraded by two levels due to few included studies and participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0006"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Foam compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam compared to sclerotherapy (any sclerosant) for telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> foam<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosing agent)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with foam</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 5 ‐ 10 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.04 higher<br/>(0.26 lower to 0.34 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 5 ‐ 10 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.12<br/>(0.44 to 10.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(11 to 265) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow up: 5 ‐ 10 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.12<br/>(1.04 to 35.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(9 to 310) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.1 lower<br/>(0.44 lower to 0.24 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> One study used participants as the unit of analysis and one study used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by two levels due to wide CIs and few participants in the included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0007"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser<br/><b>Comparison:</b> sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with laser</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.09 lower<br/>(0.25 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>593<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/>(0.40 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>262<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/>(131 to 263) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 16 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/>(0.46 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/>(57 to 270) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We were not able to pool the data due to high heterogeneity</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Two studies used participants as the unit of analysis and three studies used the number of procedures as the unit of analysis for each comparison </p> <p><sup>a</sup>We downgraded by one level due to wide CIs.<br/><sup>b</sup>We downgraded by two levels because of few included participants. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0008"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser plus sclerotherapy<br/><b>Comparison:</b> sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with laser plus sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 5.68 higher<br/>(5.14 higher to 6.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>710<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ Hyperpigmentation </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.35 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(22 to 128) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.21 to 3.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/>(4 to 60) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.44<br/>(1.69 to 3.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>596<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>649 per 1000<br/>(449 to 944) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> All studies used participants as the unit of analysis.<br/><sup>a</sup>We downgraded by two levels because of clinical heterogeneity in the included studies and the fact that the two studies were conducted by the same group of investigators.<br/><sup>b</sup>We downgraded by two levels due to having one included study. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0009"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sclerotherapy (hypertonic glucose plus polidocanol) compared to sclerotherapy (hypertonic glucose)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sclerotherapy (hypertonic glucose plus polidocanol) compared with sclerotherapy (hypertonic glucose) for telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with telangiectasias and reticular veins </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> sclerotherapy (hypertonic glucose plus POL) </p> <p><b>Comparison:</b> sclerotherapy (hypertonic glucose) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with hypertonic glucose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with hypertonic glucose plus POL</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.79 higher</p> <p>(0.50 higher to 1.09 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> hyperpigmentation </p> <p>(follow‐up: 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79</p> <p>(0.62 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>649 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>513 per 1000<br/>(403 to 656) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> matting </p> <p>(follow‐up: 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78</p> <p>(0.51 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000<br/>(179 to 421) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02</p> <p>(0.83 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>442 per 1000</p> <p>(359 to 537)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POL</b> : polidocanol; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> All studies used participants as the unit of analysis.<br/><sup>a</sup>We downgraded one level because of few participants in included studies. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD012723-tbl-0010"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy plus compression<br/><b>Comparison:</b> sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<sup>*</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy plus compression</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.09 higher<br/>(0.19 lower to 0.37 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> hyperpigmentation </p> <p>(follow‐up:4 ‐ 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.41 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>196<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/>(46 to 232) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> matting </p> <p>(follow‐up: 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.84<br/>(0.17 to 19.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/>(4 to 427) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>(follow up: 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.02 lower<br/>(0.42 lower to 0.39 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD</b>: standard mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>All studies used participants as the unit of analysis.<br/><sup>a</sup>We downgraded one level because of few participants in included studies.<br/><sup>b</sup>We downgraded two levels because of few participants and only one included study. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012723-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012723-sec-0009"></div> <section id="CD012723-sec-0010"> <h3 class="title" id="CD012723-sec-0010">Description of the condition</h3> <p>Telangiectasias, or spider veins, are dilated venules or arterioles (small superficial veins) measuring less than 1.0 mm in diameter and occurring predominantly in the lower extremities (<a href="./references#CD012723-bbs2-0082" title="ThomsonL . Sclerotherapy of telangiectasias or spider veins in the lower limb: a review. Journal of Vascular Nursing2016;34(2):61-2. [PMID: 27210454]">Thomson 2016</a>). Reticular veins have a diameter less than 3.0 mm and are often tortuous and located in the subdermal or subcutaneous tissue (<a href="./references#CD012723-bbs2-0053" title="EklofB , RutherfordRB , BerganJJ , CarpentierPH , GloviczkiP , KistnerRL , et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40(6):1248-52. [PMID: 15622385]">Eklof 2004</a>; <a href="./references#CD012723-bbs2-0069" title="PorterJM , MonetaGL . Reporting standards in venous disease: an update. International Consensus Committee on Chronic Venous Disease. Journal of Vascular Surgery1995;21(4):635-45. [PMID: 7707568]">Porter 1995</a>). Their cause is unknown. Patients may be asymptomatic or can report pain, burning or itching. Risk factors include family history, pregnancy, local trauma, obesity and hormonal factors (<a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>). </p> <p>The diagnoses of telangiectasias and reticular veins are clinical and made according to the Clinical, Etiological, Anatomical and Pathophysiological (CEAP) classification system for chronic venous disorders in the lower limb. CEAP classification comprises seven main categories: C0 to C6, and telangiectasias are classified as C1 (<a href="./references#CD012723-bbs2-0053" title="EklofB , RutherfordRB , BerganJJ , CarpentierPH , GloviczkiP , KistnerRL , et al. Revision of the CEAP classification for chronic venous disorders: consensus statement. Journal of Vascular Surgery2004;40(6):1248-52. [PMID: 15622385]">Eklof 2004</a>; <a href="./references#CD012723-bbs2-0064" title="LurieF , PassmanM , MeisnerM , DalsingM , MasudaE , WelchH , et al. The 2020 update of the CEAP classification system and reporting standards. Journal of Vascular Surgery2020;8(3):342-52. [DOI: 10.1016/j.jvsv.2019.12.075]">Lurie 2020</a>). </p> <p>C0 ‐ no visible or palpable signs of venous disease<br/>C1 ‐ telangiectasia or reticular veins (thread veins)<br/>C2 ‐ varicose veins (diameter of 3.0 mm or more)<br/>C3 ‐ oedema<br/>C4 ‐ changes in the skin and subcutaneous tissue: pigmentation (C4a), eczema (C4a), lipodermatosclerosis (C4b), atrophic blanche (C4b), or corona phlebectatica (C4c)<br/>C5 ‐ healed venous ulcer<br/>C6 ‐ active venous ulcer </p> <p>The incidence of telangiectasias increases with age (<a href="./references#CD012723-bbs2-0075" title="SchwartzL , MaxwellH . Sclerotherapy for lower limb telangiectasias. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD008826. [DOI: 10.1002/14651858.CD008826.pub2] [PMID: 22161437]">Schwartz 2011</a>). Telangiectasias on the lower limbs are very common and have been found in 41% of women over the age of 50 years (<a href="./references#CD012723-bbs2-0068" title="MujadzicM , RitterEF , GivenKS . A novel approach for the treatment of spider veins. Aesthetic Surgery Journal2015;35(7):NP221-9. [PMID: 26246022]">Mujadzic 2015</a>). They can be considered an important aesthetic or cosmetic problem (<a href="./references#CD012723-bbs2-0057" title="HercogovaJ , BrazziniB , HautmannG , GhersetichI , LottiT . Laser treatment of cutaneous vascular lesions: face and leg telangiectases. Journal of the European Academy of Dermatology and Venereology2002;16(1):12-8. [PMID: 11952285]">Hercogova 2002</a>). The presence of telangiectasias may be associated with the insufficiency of major venous systems; approximately 50% to 62% of insufficient perforating veins are found in the presence of telangiectasias (<a href="./references#CD012723-bbs2-0049" title="AndradeAR , PittaGB , CastroAA , Miranda-JúniorF . Evaluation of venous reflux by color duplex scanning in patients with varicose veins of the lower limbs: correlation with clinical severity by CEAP classification [Avaliação do refluxo venoso superficial ao mapeamento dúplex em portadores de varizes primárias de membros inferiores: correlação com a gravidade clínica da classificação CEAP]. Jornal Vascular Brasileiro2009;8(1):14-20.">Andrade 2009</a>). </p> </section> <section id="CD012723-sec-0011"> <h3 class="title" id="CD012723-sec-0011">Description of the intervention</h3> <p>Treatments for telangiectasias and reticular veins include sclerotherapy, laser therapy, intense pulsed light treatment, microphlebectomy and thermocoagulation. These techniques can be used in combination to maximise the effects and avoid any damage from the individual techniques. The most common treatment for telangiectasias is sclerotherapy (<a href="./references#CD012723-bbs2-0075" title="SchwartzL , MaxwellH . Sclerotherapy for lower limb telangiectasias. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD008826. [DOI: 10.1002/14651858.CD008826.pub2] [PMID: 22161437]">Schwartz 2011</a>), which is a technique or group of techniques for the destruction of spider veins via the injection of a medication that destroys the vein endothelium, leading to occlusion and subsequent fibrosis. Sclerosing agents are injected into the vein using hypodermic needles until the area around the puncture site blanches, or resistance can be felt. The injection is immediately discontinued if there is extravasation. Individual injections use between 0.1 mL and 0.5 mL of sclerosing agent for each telangiectasias area, although larger volumes of the sclerosing agent are required for larger veins (<a href="./references#CD012723-bbs2-0087" title="Worthington-KirschRL . Injection sclerotherapy. Seminars in Interventional Radiology2005;22(3):209-17. [PMID: 21326695]">Worthington‐Kirsch 2005</a>). There are many sclerosing agents and they are generally categorised as detergents or osmotic or chemical irritants. These agents cause endothelial damage that results in blocking the vein (vessel occlusion) and the subsequent disappearance of the vessel being treated (<a href="./references#CD012723-bbs2-0084" title="Vitale-LewisVA . Aesthetic treatment of leg veins. Aesthetic Surgery Journal2008;28(5):573-83. [PMID: 19083582]">Vitale‐Lewis 2008</a>). Foam sclerotherapy mixes gas and fluid sclerosing agents between two syringes (<a href="./references#CD012723-bbs2-0081" title="TessariL , CavezziA , FrulliniA . Preliminary experience with a new sclerosing foam in the treatment of varicose veins. Dermatologic Surgery2001;27(1):58-60. [PMID: 11231246]">Tessari 2001</a>). Foam with detergent sclerosants have a more efficient effect as a result of increasing both dwell time and contact area. This increase in efficiency also allows for lower sclerosing doses (<a href="./references#CD012723-bbs2-0087" title="Worthington-KirschRL . Injection sclerotherapy. Seminars in Interventional Radiology2005;22(3):209-17. [PMID: 21326695]">Worthington‐Kirsch 2005</a>). Foam is associated with side effects such as microthrombi, matting and transient visual disturbance (<a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>). These adverse effects may also occur with conventional sclerotherapy. </p> <p>Laser therapy is used for the treatment of telangiectasias in people with veins of a diameter less than a 30 gauge needle. Patients with a phobia to needles or allergy to certain sclerosing agents can also benefit from this technique. There are several types of lasers for the treatment of telangiectasias, with varying wavelengths between 532 nm to 1064 nm (<a href="./references#CD012723-bbs2-0066" title="MeestersAA , PitassiLH , CamposV , WolkerstorferA , DierickxCC . Transcutaneous laser treatment of leg veins. Lasers in Medical Science2014;29(2):481-92. [PMID: 24220848]">Meesters 2014</a>). Treatment with a Nd:YAG 1064 nm laser has shown similar results to sclerotherapy (<a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>). The side effects of laser therapy in the treatment of telangiectasias include erythema, crusting, swelling, and blistering (<a href="./references#CD012723-bbs2-0083" title="TierneyE , HankeCW . Randomized controlled trial: comparative efficacy for the treatment of facial telangiectasias with 532 nm versus 940 nm diode laser. Lasers in Surgery and Medicine2009;41(8):555-62. [PMID: 19746429]">Tierney 2009</a>). Laser therapy may cause less pain but may also result in complications such as spotting (<a href="./references#CD012723-bbs2-0068" title="MujadzicM , RitterEF , GivenKS . A novel approach for the treatment of spider veins. Aesthetic Surgery Journal2015;35(7):NP221-9. [PMID: 26246022]">Mujadzic 2015</a>). </p> <p>Intense Pulsed Light (IPL) is similar to laser therapy, as high‐intensity light sources emit polychromatic light ranging within the 515 to 1200 nm wavelength spectrum. The treatment of vascular lesions with IPL depends on the type and size of vessels, with angiomas and spider veins demonstrating the best response (<a href="./references#CD012723-bbs2-0054" title="GoldbergDJ . Current trends in intense pulsed light. Journal of Clinical and Aesthetic Dermatology2012;5(6):45-53. [PMID: 22768357]">Goldberg 2012</a>). There are many clinical indications for treatment with IPL (<a href="./references#CD012723-bbs2-0072" title="RaulinC , GreveB , GremaH . IPL technology: a review. Lasers in Surgery and Medicine2003;32(2):78-87. [PMID: 12561039]">Raulin 2003</a>). IPL is indicated for the treatment of unwanted hair growth, vascular lesions, pigmented lesions, acne vulgaris, photo damage and skin rejuvenation (<a href="./references#CD012723-bbs2-0050" title="BabilasP , SchremlS , SzeimiesRM , LandthalerM . Intense pulsed light (IPL): a review. Lasers in Surgery and Medicine2010;42(2):93-104. [PMID: 20166155]">Babilas 2010</a>). The negative side effects of IPL include vesicles, burns, erosions, blisters and crust formation, and hypo‐ and hyperpigmentations are also common (<a href="./references#CD012723-bbs2-0080" title="StanglS , HadshiewI , KimmigWO . Side effects and complications using intense pulsed light (IPL) sources. Medical Laser Application2008;23(1):15-20.">Stangl 2008</a>). </p> <p>Microphlebectomy is performed using hooks which enable venous extraction through minimal skin incisions or even needle punctures. Ambulatory microphlebectomy is indicated in varicose veins in any part of the body, such as arms, the periorbital, abdomen and dorsum (<a href="./references#CD012723-bbs2-0071" title="RameletAA . Phlebectomy. Technique, indications and complications. International Angiology2002;21(2-1):46-51.">Ramelet 2002</a>). </p> <p>Thermocoagulation or the radiofrequency energy method is another technique for the treatment of telangiectasias or reticular veins. The method is based on the production of high‐frequency waves, at 4 ΜΗz, transmitted through a thin needle, which causes thermal damage in the veins (<a href="./references#CD012723-bbs2-0051" title="ChadornneauJM . Treatment of the télangiectasies by the technique of thermocoagulation. Study on 50 patients. fcaresystems.com/wp-content/uploads/2012/11/Clinical-study-on-50-patients.pdf (accessed prior to 26 June 2017).">Chadornneau 2012</a>). </p> </section> <section id="CD012723-sec-0012"> <h3 class="title" id="CD012723-sec-0012">How the intervention might work</h3> <p>All the above techniques cause lesions in the vascular endothelium and consequently result in the disappearance of the target vessel. </p> <p>In sclerotherapy, the ideal sclerosant causes full destruction of the vessel wall and minimal thrombus formation. Incomplete destruction of the wall or local thrombosis may lead to recanalisation. The ideal agent would also be nontoxic, easily manipulated, and painless (<a href="./references#CD012723-bbs2-0087" title="Worthington-KirschRL . Injection sclerotherapy. Seminars in Interventional Radiology2005;22(3):209-17. [PMID: 21326695]">Worthington‐Kirsch 2005</a>). </p> <p>Laser and IPL therapies are alternative options but have a high cost compared to sclerotherapy. Both techniques act by exposing the red elements of blood to light energy. Oxyhaemoglobin is the major chromophore in blood vessels, with two absorption bands in the visible light spectrum at 542 nm and 577 nm. Following absorption by oxyhaemoglobin, light energy is converted to thermal energy, which diffuses in the blood vessel, causing photocoagulation, mechanical injury, and finally thrombosis and occlusion of the target vessel (<a href="./references#CD012723-bbs2-0067" title="MicaliG , GerberPA , LacarrubbaF , SchaferG . Improving treatment of erythematotelangiectatic rosacea with laser and/or topical therapy through enhanced discrimination of its clinical features. Journal of Clinical and Aesthetic Dermatology2016;9(7):30-9. [PMID: 27672409]">Micali 2016</a>). </p> <p>Different laser wavelengths can be successfully used to treat vascular lesions. Each type of laser has advantages specific to its wavelength, pulse duration, spot size, and cutaneous cooling profile. The 532 to 595 nm lasers have multiple applications, treating not only telangiectasias, but also pigmentation and even fine wrinkles. The main advantage of using a 1064 nm laser is that its longer wavelength can penetrate more deeply, allowing the effective thermosclerosis of spider veins (<a href="./references#CD012723-bbs2-0055" title="GoldmanMP . Optimal management of facial telangiectasia. American Journal of Clinical Dermatology2004;5(6):423-34. [PMID: 15663339]">Goldman 2004</a>). </p> <p>A possible advantage of IPL is selective photothermolysis, in which thermal damage is confined to specific epidermal or dermal pigmented targets. Tissues surrounding these targeted structures are spared, potentially reducing nonspecific, widespread thermal injury. There are three main chromophores: haemoglobin, water, and melanin. They have broad absorption peaks of light energy, allowing them to be targeted by a range, as well as a specific wavelength of light (<a href="./references#CD012723-bbs2-0054" title="GoldbergDJ . Current trends in intense pulsed light. Journal of Clinical and Aesthetic Dermatology2012;5(6):45-53. [PMID: 22768357]">Goldberg 2012</a>). </p> <p>The advantage of microphlebectomy is minimal or no scarring, no skin necrosis and no residual hyperpigmentation (<a href="./references#CD012723-bbs2-0071" title="RameletAA . Phlebectomy. Technique, indications and complications. International Angiology2002;21(2-1):46-51.">Ramelet 2002</a>). </p> <p>Thermocoagulation is a relatively new technology with advantages such as the immediate disappearance of veins, no allergic manifestations, no pigmentation and necrosis, and applicability to all skin types (<a href="./references#CD012723-bbs2-0051" title="ChadornneauJM . Treatment of the télangiectasies by the technique of thermocoagulation. Study on 50 patients. fcaresystems.com/wp-content/uploads/2012/11/Clinical-study-on-50-patients.pdf (accessed prior to 26 June 2017).">Chadornneau 2012</a>). </p> </section> <section id="CD012723-sec-0013"> <h3 class="title" id="CD012723-sec-0013">Why it is important to do this review</h3> <p>There is a high prevalence of telangiectasias, or spider veins, and the most common age for presentation is between 30 and 50 years (<a href="./references#CD012723-bbs2-0074" title="RuckleyCV , EvansCJ , AllanPL , LeeAJ , FowkesFG . Telangiectasia in the Edinburgh Vein Study: epidemiology and association with trunk varices and symptoms. European Journal of Vascular and Endovascular Surgery2008;36(6):719-24.">Ruckley 2008</a>). The incidence increases with age and is an important aesthetic problem (<a href="./references#CD012723-bbs2-0057" title="HercogovaJ , BrazziniB , HautmannG , GhersetichI , LottiT . Laser treatment of cutaneous vascular lesions: face and leg telangiectases. Journal of the European Academy of Dermatology and Venereology2002;16(1):12-8. [PMID: 11952285]">Hercogova 2002</a>). In Brazil, the incidence of telangiectasias in young women is 50% and represents a cosmetic problem for them (<a href="./references#CD012723-bbs2-0076" title="ScuderiA , RaskinB , Al AssalF , ScuderiP , ScuderiMA , RivasCE , et al. The incidence of venous disease in Brazil based on the CEAP classification. International Angiology2002;21(4):316-21. [PMID: 12518109]">Scuderi 2002</a>). A research report from Poland, including women aged between 18 and 60, found a telangiectasias incidence of 27% (<a href="./references#CD012723-bbs2-0061" title="KarchA , KasperczykJ . Somatic risk factors for chronic venous insufficiency in women: preliminary report [Somatyczne uwarunkowania ryzyka przewleklej niewydolnosci zylnej u kobiet: doniesienie wstepne]. Wiadomosci Lekarskie (Warsaw, Poland)2002;55 (Suppl 1):212-6. [PMID: 15002244]">Karch 2002</a>). Sclerotherapy, the treatment most often used for telangiectasias, has low costs but is not free from complications. Laser therapy is a safe and efficacious treatment for telangiectasias and can be achieved with multiple lasers (<a href="./references#CD012723-bbs2-0065" title="McCoppinHH , HovenicWW , WheelandRG . Laser treatment of superficial leg veins: a review. Dermatologic Surgery2011;37(6):729-41. [PMID: 21605232]">McCoppin 2011</a>). IPL is versatile, which allows the treatment of both vascular and pigmented lesions (<a href="./references#CD012723-bbs2-0085" title="WallTL . Current concepts: laser treatment of adult vascular lesions. Seminars in Plastic Surgery2007;21(3):147-58. [PMID: 20567666]">Wall 2007</a>). IPL may offer an advantage due to its selective photothermolysis but has a high cost compared to sclerotherapy. Currently, there is a lack of evidence about which of these methods is more effective in the treatment of telangiectasias. There has been a previous Cochrane Review on sclerotherapy for telangiectasias (<a href="./references#CD012723-bbs2-0075" title="SchwartzL , MaxwellH . Sclerotherapy for lower limb telangiectasias. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD008826. [DOI: 10.1002/14651858.CD008826.pub2] [PMID: 22161437]">Schwartz 2011</a>), but none has addressed other methods for the treatment of telangiectasias. This review reports on the evidence available to enable healthcare professionals and consumers to choose the most appropriate treatment method for telangiectasias and reticular veins. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012723-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012723-sec-0014"></div> <p>To assess the effects of sclerotherapy, laser therapy, intensive pulsed light (IPL), thermocoagulation, and microphlebectomy treatments for telangiectasias and reticular veins. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012723-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012723-sec-0015"></div> <section id="CD012723-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012723-sec-0017"> <h4 class="title">Types of studies</h4> <p>We searched and considered for inclusion all randomised controlled trials (RCTs) and quasi‐RCTs that compared treatment methods for telangiectasias and reticular veins in the lower limb. We included studies that compared individual treatment methods against placebo, or that compared different sclerosing agent, or foam or laser treatment. We also included studies that used a combination of methods. </p> </section> <section id="CD012723-sec-0018"> <h4 class="title">Types of participants</h4> <p>We considered all participants, both male and female and of all ages, with telangiectasias and reticular veins in the lower limb, confirmed by either the CEAP C1 classification or the clinical assessment of a physician. We excluded people with hereditary haemorrhagic telangiectasias (HHT), mucous telangiectasias, people treated for telangiectasias or superficial vein reflux within the previous 30 days, and people undergoing a simultaneous treatment for telangiectasias and superficial vein reflux. </p> </section> <section id="CD012723-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We evaluated the following interventions:</p> <p> <ul id="CD012723-list-0001"> <li> <p>Sclerotherapy with any sclerosing agent of any dose or duration (with or without compression treatment); </p> </li> <li> <p>Laser therapy applied directly to the telangiectasias or reticular veins (any wavelength, any treatment regimen); </p> </li> <li> <p>Intensive Pulsed Light (IPL) applied directly to the telangiectasias or reticular veins (any wavelength, any treatment regimen); </p> </li> <li> <p>Thermocoagulation applied directly to the telangiectasias or reticular veins;</p> </li> <li> <p>Microphlebectomy in reticular veins.</p> </li> </ul> </p> <p>Comparisons:</p> <p> <ul id="CD012723-list-0002"> <li> <p>Sclerotherapy versus placebo;</p> </li> <li> <p>Sclerotherapy versus sclerotherapy;</p> </li> <li> <p>Sclerotherapy versus laser therapy;</p> </li> <li> <p>Sclerotherapy versus IPL;</p> </li> <li> <p>Sclerotherapy versus thermocoagulation;</p> </li> <li> <p>Sclerotherapy versus microphlebectomy;</p> </li> <li> <p>Laser therapy versus placebo;</p> </li> <li> <p>Laser therapy versus laser therapy;</p> </li> <li> <p>Laser therapy versus IPL therapy;</p> </li> <li> <p>Laser therapy versus thermocoagulation;</p> </li> <li> <p>Laser therapy versus microphlebectomy;</p> </li> <li> <p>IPL versus placebo;</p> </li> <li> <p>IPL versus IPL therapy;</p> </li> <li> <p>IPL versus thermocoagulation;</p> </li> <li> <p>IPL versus microphlebectomy;</p> </li> <li> <p>Thermocoagulation versus placebo;</p> </li> <li> <p>Thermocoagulation versus microphlebectomy;</p> </li> <li> <p>Any combination of the above treatments versus any combination.</p> </li> </ul> </p> </section> <section id="CD012723-sec-0020"> <h4 class="title">Types of outcome measures</h4> <section id="CD012723-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012723-list-0003"> <li> <p>Clinically‐ or photographically‐assessed resolution or improvement (or both) of telangiectasias: resolution or improvement were measured by clear diagnostic scales, e.g. vessel clearance &lt; 20%, 20 to 40%, 40 to 60%, 60 to 80%, &gt; 80% (<a href="./references#CD012723-bbs2-0077" title="ShammaAR , RamadanFM , VonderliethK . Transdermal laser treatment of facial telangiectasia - comparison of the 532 nm KTP to the 940 nm diode wavelength. In: International Vein Congress. Miami, FL, April 2004.">Shamma 2005</a>) or study definitions </p> </li> <li> <p>Adverse events (including hyperpigmentation, matting, allergy, bruising, anaphylaxis, necrosis of the skin) </p> </li> </ul> </p> </section> <section id="CD012723-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012723-list-0004"> <li> <p>Pain during procedure and post‐procedure: pain was measured by clear diagnostic scales during the procedure and 24 hours post‐procedure, e.g. visual analogue pain scale (VAS), used for determining the pain level during laser treatment. Pain is graded by the participant with the help of a coloured gradient and graduated line from 1 to 10 (<a href="./references#CD012723-bbs2-0062" title="KozarevJ . Use of long pulse Nd:YAG 1064nm laser for treatment of rosacea telangiectatica. Journal of the Laser and Health Academy2011;1:33-6.">Kozarev 2011</a>) </p> </li> <li> <p>Recurrence: recurrence was measured by clear diagnostic scales until 30 days after the procedure, e.g. vessel clearance &lt; 20%, 20 to 40%, 40 to 60%, 60 to 80%, &gt; 80% (<a href="./references#CD012723-bbs2-0077" title="ShammaAR , RamadanFM , VonderliethK . Transdermal laser treatment of facial telangiectasia - comparison of the 532 nm KTP to the 940 nm diode wavelength. In: International Vein Congress. Miami, FL, April 2004.">Shamma 2005</a>) </p> </li> <li> <p>Time to resolution (time unit: days)</p> </li> <li> <p>Quality of life: any scale of quality of life, e.g. Aberdeen Varicose Vein Severity Score (AVVSS) (<a href="./references#CD012723-bbs2-0078" title="SmithJJ , GarrattAM , GuestM , GreenhalghRM , DaviesAH . Evaluating and improving health-related quality of life in patients with varicose veins. Journal of Vascular Surgery1999;30(4):710-9.">Smith 1999</a>) </p> </li> </ul> </p> </section> </section> </section> <section id="CD012723-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012723-sec-0024"> <h4 class="title">Electronic searches</h4> <p>The Cochrane Vascular Information Specialist (CIS) conducted systematic searches of the following databases for RCTs without language, publication year or publication status restrictions: </p> <p> <ul id="CD012723-list-0005"> <li> <p>Cochrane Vascular Specialised Register via the Cochrane Register of Studies (CRS‐Web) (searched 16 March 2021); </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL; 2021, Issue 2) via the Cochrane Register of Studies Online (CRSO); </p> </li> <li> <p>MEDLINE (Ovid MEDLINE Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE Daily and Ovid MEDLINE) (searched 16 March 2021); </p> </li> <li> <p>Embase Ovid (searched 16 March 2021);</p> </li> <li> <p>AMED Ovid (searched 16 March 2021);</p> </li> <li> <p>CINAHL Ebsco (searched 16 March 2021).</p> </li> </ul> </p> <p>The CIS modelled search strategies for other databases on the search strategy designed for CENTRAL. Where appropriate,we combined them with adaptations of the highly sensitive search strategy designed by the Cochrane Collaboration for identifying RCTs and controlled clinical trials (as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> Chapter 6, <a href="./references#CD012723-bbs2-0063" title="LefebvreC , ManheimerE , GlanvilleJ . Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Lefebvre 2011</a>). Search strategies for major databases are provided in <a href="./appendices#CD012723-sec-0136">Appendix 1</a>. </p> <p>The Information Specialist searched the following trial registries on 16 March 2021:</p> <p> <ul id="CD012723-list-0006"> <li> <p>World Health Organization International Clinical Trials Registry Platform (<a href="http://who.int/trialsearch" target="_blank">who.int/trialsearch</a>); </p> </li> <li> <p>ClinicalTrials.gov (<a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>). </p> </li> </ul> </p> <p>The authors performed additional searches in LILACS and IBECS databases. The search strategy was designed by the authors and checked by the Cochrane Information Specialist of Cochrane Brazil. See <a href="./appendices#CD012723-sec-0137">Appendix 2</a> for details of the search strategy used for the authors' search (searched 17 March 2021). </p> </section> <section id="CD012723-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We checked the bibliographies of included trials for further references to relevant trials. We contacted specialists in the field, manufacturers and authors of the included trials for any possible unpublished data. </p> </section> </section> <section id="CD012723-sec-0026"> <h3 class="title" id="CD012723-sec-0026">Data collection and analysis</h3> <section id="CD012723-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We examined the titles and abstracts to select the relevant reports after merging the search results and removing duplicate records. Three review authors (LCUN, DGC and RLGF) independently evaluated the trials to determine if they were appropriate to include. We resolved disagreements by discussion within the review team. We then retrieved and examined the full text of the relevant trials for compliance with eligibility criteria. Where a trial did not meet the eligibility criteria, we excluded the trial and documented the reason for exclusion. </p> </section> <section id="CD012723-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (LCUN, DGC and RLGF) independently extracted and collected data on paper data extraction forms. We resolved disagreements by discussion within the review team. We collected the following information. </p> <p> <ul id="CD012723-list-0007"> <li> <p>Study features: publication details (e.g. year, country, authors); study design; population data (e.g. age, comorbidities, severity of telangiectasias, duration, history of treatments, and responses); details of intervention (e.g. manufacture, material, site of insertion, additional procedures); number of participants randomised into each treatment group; the number of participants in each group who failed treatment; the numbers of participants lost to follow‐up; the duration of follow‐up; cost of treatment; sources of funding; study authors’ potential conflicts of interest. </p> </li> <li> <p>Outcomes: types of outcomes measured; timing of outcomes.</p> </li> </ul> </p> </section> <section id="CD012723-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (LCUN, DGC and RLGF), independently assessed the included studies for risks of bias, using Cochrane's risk of bias tool, described in Section 8.5 of the <i>Cochrane Handbook for Systematic Reviews of interventions</i> (<a href="./references#CD012723-bbs2-0058" title="HigginsJP , GreenS , editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.">Higgins 2011</a>). We planned to resolve disagreements by discussion within the review team, if necessary. </p> <p>We assessed the following domains and rated them at low, unclear, or high risk of bias: </p> <p> <ul id="CD012723-list-0008"> <li> <p>random sequence generation;</p> </li> <li> <p>adequate concealment of allocation;</p> </li> <li> <p>blinding of participants and personnel;</p> </li> <li> <p>blinding of outcome assessment;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>selective outcome reporting; and</p> </li> <li> <p>other potential threats to validity.</p> </li> </ul> </p> <p>We reported the assessments for each individual study in the risk of bias tables located in the '<a href="./references#CD012723-sec-0148" title="">Characteristics of included studies</a>' section. We planned to contact the study author(s) to seek clarification in cases of uncertainty over data. </p> </section> <section id="CD012723-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>We used the risk ratio (RR) for dichotomous data and mean difference (MD) for continuous data with the same scale, or standardised mean difference (SMD) for continuous data with different scales, all with 95% confidence intervals (CIs). </p> </section> <section id="CD012723-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>We considered each participant as the unit of analysis. For trials that considered multiple interventions in the same group, we analysed only the partial data of interest. Studies with a split‐body design were treated as cross‐over trials as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012723-bbs2-0059" title="HigginsJP , EldridgeS , Li T (editors). Chapter 23: Including variants on randomized trials. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021a</a>). </p> </section> <section id="CD012723-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We analysed only the available data and contacted the trial authors to request missing data. We reported dropout rates in the '<a href="./references#CD012723-sec-0148" title="">Characteristics of included studies</a>' tables of the review, and we used intention‐to‐treat analysis. </p> </section> <section id="CD012723-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We inspected forest plots visually to consider the direction and magnitude of effects and the degree of overlap between confidence intervals. We quantified inconsistency among the pooled estimates using the I<sup>2</sup> statistic (where I<sup>2</sup> = ((Q ‐ df)/Q) x 100% where Q is the Chi<sup>2</sup> statistic, and 'df' represents the degree of freedom). This illustrates the percentage of the variability in effect estimates resulting from heterogeneity rather than sampling error (<a href="./references#CD012723-bbs2-0052" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). We interpreted the thresholds for the I<sup>2</sup> statistic as follows: 0 to 30% = low heterogeneity; 30% to 60% = moderate heterogeneity; 60% to 90% = substantial heterogeneity, and more than 90% = considerable heterogeneity (<a href="./references#CD012723-bbs2-0052" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al. editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 6 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD012723-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>We planned to assess the presence of publication bias and other reporting bias using funnel plots if we identified sufficient studies (more than 10) for inclusion in the meta‐analysis (<a href="./references#CD012723-bbs2-0060" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>). </p> </section> <section id="CD012723-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We synthesised the data using Review Manager 5 (<a href="./references#CD012723-bbs2-0073" title="Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: The Cochrane Collaboration, 2020.">Review Manager 2020</a>). We planned to use the fixed‐effect model to synthesise the data if there were low to moderate levels of heterogeneity. If there was substantial heterogeneity, we planned to use a random‐effects model. If there was considerable heterogeneity, we planned not to undertake a meta‐analysis but to describe the data narratively in the text. As we identified clinical heterogeneity due to differences in, for example, study designs or sclerosing agents, we used a random‐effects model to synthesize the data. </p> </section> <section id="CD012723-sec-0036"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If sufficient data were available, we planned to perform subgroup analyses for the following: </p> <p> <ul id="CD012723-list-0009"> <li> <p>interventions: types of sclerosant, IPL and laser wave lengths; and combination of methods; </p> </li> <li> <p>participant characteristics: age (e.g. youth (15 years to 24 years), adults (25 years to 64 years) and seniors (65 years and over)), gender and race. </p> </li> </ul> </p> </section> <section id="CD012723-sec-0037"> <h4 class="title">Sensitivity analysis</h4> <p>If an adequate number of studies were available, we planned to perform sensitivity analysis based on allocation concealment (high, low, or unclear) and blinding of outcome assessment (high, low, or unclear). We planned to carry out sensitivity analyses by excluding those trials that we judged to be at high risk of bias according to <a href="./references#CD012723-bbs2-0060" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>. We were not able to do this, as comparisons did not include sufficient studies. </p> </section> <section id="CD012723-sec-0038"> <h4 class="title">Summary of findings and assessment of the certainty of the evidence</h4> <p>We prepared summary of findings tables to provide the key information presented in the review comparing treatments in participants with telangiectasias and reticular veins. We prepared summary of findings tables for each comparison at one time point, using the outcomes described in <a href="#CD012723-sec-0020">Types of outcome measures</a>: </p> <p> <ul id="CD012723-list-0010"> <li> <p>clinically‐ or photographically‐assessed resolution or improvement, or both, of telangiectasias;</p> </li> <li> <p>adverse events (hyperpigmentation and matting);</p> </li> <li> <p>pain during procedure and post‐procedure;</p> </li> <li> <p>recurrence;</p> </li> <li> <p>time to resolution;</p> </li> <li> <p>quality of life.</p> </li> </ul> </p> <p>We assessed the certainty of the evidence for each outcome as high, moderate, low or very low, based on the criteria of risk of bias, inconsistency, indirectness, imprecision, and publication bias, using the GRADE approach (<a href="./references#CD012723-bbs2-0056" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Grade 2004</a>). We based the tables on methods described in Chapters 11 and 12 of the <i>Cochrane Handbook</i>, and justified any departures from the standard methods (<a href="./references#CD012723-bbs2-0056" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Grade 2004</a>; <a href="./references#CD012723-bbs2-0060" title="HigginsJP , ThomasJ , ChandlerJ , CumpstonM , LiT , PageMJ , et al (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.2 (updated February 2021). The Cochrane Collaboration, 2021. Available from www.training.cochrane.org/handbook.">Higgins 2021b</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012723-sec-0039" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012723-sec-0039"></div> <section id="CD012723-sec-0040"> <h3 class="title">Description of studies</h3> <section id="CD012723-sec-0041"> <h4 class="title">Results of the search</h4> <p>The searches in the literature databases and trial registries identified 2649 reports, which we reduced to 2279 potentially relevant records after deduplication. We assessed 48 full‐text articles for eligibility, and identified 35 studies which met the review inclusion criteria (<a href="#CD012723-fig-0001">Figure 1</a>). We excluded 10 studies and identified three ongoing studies. </p> <div class="figure" id="CD012723-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD012723-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD012723-sec-0042"> <h4 class="title">Included studies</h4> <p>See <a href="./references#CD012723-sec-0148" title="">Characteristics of included studies</a>. </p> <section id="CD012723-sec-0043"> <h5 class="title">Type of study</h5> <p>The characteristics of the 35 included studies are shown in <a href="./references#CD012723-sec-0148" title="">Characteristics of included studies</a>. All 35 included studies were RCTs published between 1987 and 2021 (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> <p>Of the 35 studies, nine evaluated participants with telangiectasias (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>), and 26 studied participants with telangiectasias and reticular varicose veins up to 3.0 mm in diameter (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> <p>Only five studies presented a sample size calculation (<a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>). </p> </section> <section id="CD012723-sec-0044"> <h5 class="title">Setting</h5> <p>Ten RCTs were conducted in the USA (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>, <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>), five in Switzerland (<a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>), three in Spain (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>), three in Brazil (<a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>); four in Germany (<a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>), two in France (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>), one each in China (<a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>), in Turkey (<a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>), in Australia (<a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>), in Canada (<a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>), in Denmark (<a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>), in Romania (<a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>), in Vietnam (<a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>) and in Mexico (<a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>). </p> </section> <section id="CD012723-sec-0045"> <h5 class="title">Unit of analysis</h5> <p>Of the 35 included studies, 18 used a split‐body design, comparing groups in an opposite leg or a lower limb quadrant (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>). The remaining 17 studies used the participant as the unit of analysis (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> </section> <section id="CD012723-sec-0046"> <h5 class="title">Study participants</h5> <p>The 35 included studies provided data for 3632 participants. The smallest study included 13 participants (<a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>) and the largest included 720 participants (<a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>). Thirteen studies included up to a maximum of 30 participants (<a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>, n = 13; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>, n = 14; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>, n = 15; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>, n = 20; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>, n = 20; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>, n = 20; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>, n = 20; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>, n = 20; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>, n = 20; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>, n = 21; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>, n = 24; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>, n = 30; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>, n = 30). Twelve studies included up to 100 participants (<a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>, n = 93; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>, n = 48; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>, n = 50; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>, n = 53; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>, n = 56; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>, n = 58; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>, n = 60; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>, n = 90; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>, n = 63; <a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>, n = 75; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>, n = 81; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>, n = 100). Ten studies included more than 100 participants (<a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>, n = 105; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>, n = 110; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>, n = 115; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>, n = 129; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>, n = 150; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>, n= 285; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>, n = 288; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>, n = 316; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>, n = 320; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>, n = 720). </p> <p>All included studies evaluated participants with CEAP C1, telangiectasias or reticular veins (diameter less than 3.0 mm) in the lower limb. Three studies included participants classified CEAP C2, but these data are not included in this review (<a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> <p>Most studies (n = 25) evaluated only women (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>). Eight studies analysed men and women (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). Two studies did not report the gender of the participants (<a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>). </p> <p>Five includes studies did not provide data about the age of the participants (<a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>), and another 10 studies reported the age range without the mean (<a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). The age of participants ranged from 17 to 80 years. </p> <p>Twelve studies reported data on the skin photo type by Fitzpatrick’s classification: Photo type I to III (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>); Photo type I to IV (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>); Photo type IV (<a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>); Photo type II to IV (<a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>). </p> </section> <section id="CD012723-sec-0047"> <h5 class="title">Interventions</h5> <p>There were six sclerosing agents in the included studies: polidocanol (0.25% to 3%), sodium tetradecyl sulfate (STS) (0.25% to 1%), hypertonic saline (20% to 23.4%), chromated glycerin (72%), hypertonic glucose (70%), and dextrose. </p> <p>Four studies compared any sclerosing agent versus placebo (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a> and <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a> compared polidocanol versus placebo. <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a> compared polidocanol versus STS versus hypertonic saline versus placebo; and <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a> compared polidocanol versus STS versus placebo). </p> <p>Nine studies compared sclerosing liquid versus sclerosing liquid (<a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a> ‐ polidocanol (0.25%) versus polidocanol (0.50%) versus polidocanol (0.75%) versus polidocanol (1%); <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a> ‐ hypertonic dextrose versus STS, <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a> – hypertonic saline versus polidocanol; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a> – STS versus polidocanol; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a> – chromated glycerin versus STS; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a> – STS versus polidocanol; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a> – hypertonic saline versus polidocanol; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a> and <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a> – hypertonic glucose versus hypertonic glucose plus polidocanol). </p> <p>Five studies compared any form of foam (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>). <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a> and <a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a> compared foam versus polidocanol. <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a> compared foam versus polidocanol versus chromated glycerin and <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a> and <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a> compared two types of foam. </p> <p>Ten studies compared laser treatment (<a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>). Four types of laser were used for the treatment of telangiectasias and reticular veins: long pulsed 1064 nm Nd:YAG laser with different spot sizes, fluency and pulse duration; pulsed dye laser (PDL; 595 nm), potassium titanyl phosphate laser (KTP; 532 nm) and long pulsed 755 nm Nd:YAG. Six studies compared laser versus sclerotherapy (<a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a> – laser versus STS, <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a> – laser versus hypertonic glucose, <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a> – laser versus polidocanol (foam) versus laser plus polidocanol (foam), <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a> – laser plus polidocanol (foam) versus polidocanol (foam) and <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a> – laser versus polidocanol and <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a> – laser versus polidocanol versus hypertonic saline). Four studies compared laser versus laser (<a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a> – PDL versus Nd:YAG, <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a> – Nd:YAG versus Nd‐YAG, <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a> – KTP versus Nd:YAG, and <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a> – Nd:YAG 1064 versus Nd:YAG 755). </p> <p>Six studies compared additional therapy to the sclerosing agent or different treatment techniques of injecting sclerosing agent: <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a> and <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a> – sclerotherapy versus sclerotherapy plus compression; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a> – chromated glycerin versus chromated glycerin plus lidocaine; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a> – chromated glycerin (standard technique) versus chromated glycerin (two‐step technique), <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a> – sclerotherapy plus warfarin versus sclerotherapy plus low molecular weight heparin, and <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a> – sclerotherapy versus sclerotherapy plus sulodexide. </p> <p>One study compared sclerotherapy versus compression stockings (<a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>). </p> <p>We did not find eligible studies of the other techniques identified in our protocol (<a href="./references#CD012723-bbs2-0089" title="NakanoLC , CacioneDG , Baptista-SilvaJC , FlumignanRL . Treatment for telangiectasias and reticular veins. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012723. [DOI: 10.1002/14651858.CD012723]">Nakano 2017</a>): Intensive Pulsed Light (IPL), microphlebectomy, or thermocoagulation. </p> </section> <section id="CD012723-sec-0048"> <h5 class="title">Outcomes</h5> <p>Thirty studies evaluated our primary outcome of improvement or resolution of telangiectasias using photographs and external examination (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). Three studies evaluated improvement by direct clinical access (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>). Nineteen studies included participant satisfaction as an outcome (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> <p>Two included studies did not mention adverse effects (<a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>). The main adverse events reported by the other 33 studies are allergy, blistering, bruising, ecchymosis, hyperpigmentation, matting, microthrombosis, necrosis, scarring, swelling, transient neurological abnormality and urticaria. Four studies classified adverse events using different scales (<a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>). </p> <p>Twenty‐three studies reported pain as an outcome, using different scales (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> <p><a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a> did not report any outcomes of interest, as they studied prophylaxis of deep venous thrombosis. We report this as an adverse event. </p> <p>Only <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a> and <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a> reported quality of life (QoL) as an outcome. </p> <p>None of the 35 included studies reported on the outcomes of recurrence or time to resolution. </p> </section> </section> <section id="CD012723-sec-0049"> <h4 class="title">Excluded studies</h4> <p>See <a href="./references#CD012723-sec-0149" title="">Characteristics of excluded studies</a>. </p> <p>Of the 10 excluded studies, eight were not randomised (<a href="./references#CD012723-bbs2-0036" title="AloraMB , SternRS , ArndtKA , DoverJS . Comparison of the 595 nm long-pulse (1.5 msec) and ultralong-pulse (4 msec) lasers in the treatment of leg veins. Dermatologic Surgery1999;25(6):445-9. [PMID: 10469090]">Alora 1999</a>; <a href="./references#CD012723-bbs2-0037" title="ConradP , MaloufGM , StaceyMC . The Australian polidocanol (aethoxysklerol) study. Results at 2 years. Dermatologic Surgery1995;21(4):334-6; discussion 337-8. [PMID: 7728486]">Conrad 1995</a>; <a href="./references#CD012723-bbs2-0039" title="GilletJL , DesnosCH , LauseckerM , DanielC , GuexJJ , AllaertFA . Sclerotherapy is a safe method of treatment of chronic venous disorders in older patients: a prospective and comparative study of consecutive patients. Phlebology2017;32(4):234-40. [PMID: 27068734]">Gillet 2017</a>; <a href="./references#CD012723-bbs2-0040" title="McDanielDH , AshK , LordJ , NewmanJ , AdrianRM , ZukowskiM . Laser therapy of spider leg veins: clinical evaluation of a new long pulsed alexandrite laser. Dermatologic Surgery1999;25(1):52-8. [PMID: 9935096]">McDaniel 1999</a>; <a href="./references#CD012723-bbs2-0041" title="OmuraNE , DoverJS , ArndtKA , KauvarAN . Treatment of reticular leg veins with a 1064 nm long-pulsed Nd:YAG laser. Journal of the American Academy of Dermatology2003;48(1):76-81. [PMID: 12522374]">Omura 2003</a>; <a href="./references#CD012723-bbs2-0042" title="SadickNS . Laser treatment with a 1064-nm laser for lower extremity class I-III veins employing variable spots and pulse width parameters. Dermatologic Surgery2003;29(9):916-9. [PMID: 12930332]">Sadick 2003</a>; <a href="./references#CD012723-bbs2-0044" title="WeissRA , WeissMA . Incidence of side effects in the treatment of telangiectasias by compression sclerotherapy: hypertonic saline vs. polidocanol. Journal of Dermatologic Surgery and Oncology1990;16(9):800-4. [PMID: 2398199]">Weiss 1990</a>; <a href="./references#CD012723-bbs2-0045" title="WooWK , JasimZF , HandleyJM . 532-nm Nd:YAG and 595-nm pulsed dye laser treatment of leg telangiectasia using ultralong pulse duration. Dermatologic Surgery2003;29(12):1176-80; discussion 1180. [PMID: 14725658]">Woo 2003</a>). <a href="./references#CD012723-bbs2-0043" title="SpendelS , PrandlEC , SchintlerMV , SieglA , WittgruberG , HellbomB , et al. Treatment of spider leg veins with the KTP (532 nm) laser - a prospective study. Lasers in Surgery and Medicine2002;31(3):194-201. [PMID: 12224093]">Spendel 2002</a> was excluded for not comparing techniques. <a href="./references#CD012723-bbs2-0038" title="DinsdaleG , MurrayA , MooreT , FergusonJ , WilkinsonJ , RichardsH , et al. A comparison of intense pulsed light and laser treatment of telangiectases in patients with systemic sclerosis: a within-subject randomized trial. Rheumatology (Oxford, England)2014;53(8):1422-30. [PMID: 24625502]">Dinsdale 2014</a> was excluded for not separating telangiectasias of the face and limbs. </p> </section> <section id="CD012723-sec-0050"> <h4 class="title">Ongoing studies</h4> <p>We identified three ongoing studies (<a href="./references#CD012723-bbs2-0046" title="NCT04132323. Clinical efficacy of low concentrate detergents versus hypertonic glucose for treatment of telangiectasia: a prospective randomized clinical trial. clinicaltrials.gov/ct2/show/NCT04132323 (first received 16 October 2019). ">NCT04132323</a>; <a href="./references#CD012723-bbs2-0047" title="NCT04690803. The effect of cooling on sclerotherapy efficacy. clinicaltrials.gov/ct2/show/NCT04690803 (first received 31 December 2020). ">NCT04690803</a>; <a href="./references#CD012723-bbs2-0048" title="Zaleski-LarsenL , BoltonJ , GoldmanM . A comparative of the effect of non-chromated glycerin solution with 1% lidocaine formulated (2:1) with and without epinephrine used in combination with foam polidocanol on adverse events and efficacy following sclerotherapy for reticular veins and telangiectasias of the lower extremities. Phlebology2017;32(2 (Suppl 1)):53-4. ">Zaleski‐Larsen 2017</a>). See <a href="./references#CD012723-sec-0150" title="">Characteristics of ongoing studies</a>. </p> </section> </section> <section id="CD012723-sec-0051"> <h3 class="title">Risk of bias in included studies</h3> <p>See <a href="#CD012723-fig-0002">Figure 2</a> and <a href="#CD012723-fig-0003">Figure 3</a> for the risk of bias of all included studies summary, and the risk of bias tables of the <a href="./references#CD012723-sec-0148" title="">Characteristics of included studies</a> for further details. </p> <div class="figure" id="CD012723-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012723-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> </div> <div class="figure" id="CD012723-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012723-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD012723-sec-0052"> <h4 class="title">Allocation</h4> <section id="CD012723-sec-0053"> <h5 class="title">Random sequence generation</h5> <p>We ranked random sequence generation (selection bias) at low risk of bias in 15 studies (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>). We rated two studies at high risk of bias because scheduled appointments for randomisation were used (<a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>), and legs laterality right and left were used (<a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>). The remaining 18 included studies were considered at unclear risk of bias due to lack of information (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). </p> </section> <section id="CD012723-sec-0054"> <h5 class="title">Allocation concealment</h5> <p>We rated only five included studies at low risk of bias (<a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>). We considered the remaining 30 studies to have an unclear risk of bias, due to lack of information. </p> </section> </section> <section id="CD012723-sec-0055"> <h4 class="title">Blinding</h4> <section id="CD012723-sec-0056"> <h5 class="title">Blinding of participants and personnel</h5> <p>We judged 13 of the studies to be at low risk of bias for blinding of participants and personnel (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). We rated nine studies at unclear risk of bias due to lack of information (<a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>), and 13 studies were considered to have a high risk of bias because the participants were not blinded (<a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>). </p> </section> <section id="CD012723-sec-0057"> <h5 class="title">Blinding of outcome assessment</h5> <p>We judged 26 studies to have a low risk of bias (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). Eight studies were considered to have an unclear risk of bias due to lack of information (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>). One study was considered at high risk of bias because outcome assessment was not blinded (<a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>). </p> </section> </section> <section id="CD012723-sec-0058"> <h4 class="title">Incomplete outcome data</h4> <p>We rated 24 studies at low risk of bias (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>; <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>; <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>; <a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). Nine studies were at unclear risk of bias (<a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>;<a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a><a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a>; <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>). We judged two studies to have a high risk of bias, because four people were "lost of view", as per personal communication with author (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>), and because three participants were lost to follow‐up, and two left because of intolerance to pain in <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>. </p> </section> <section id="CD012723-sec-0059"> <h4 class="title">Selective reporting</h4> <p>Only <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a> was considered at low risk of bias. We considered two studies to be at high risk of bias, as some adverse events were not statistically analysed by sclerosing agent used and descriptive data are not provided (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>). We judged the remaining 32 included studies to have an unclear risk of bias due to lack of information. </p> </section> <section id="CD012723-sec-0060"> <h4 class="title">Other potential sources of bias</h4> <p>Only <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a> was considered to have a high risk of bias because the participants received separate simultaneous treatments and analysis, meaning that the outcomes could have been impacted due to the carry‐over effect. The remaining 34 studies had no clear evidence of other bias. </p> </section> </section> <section id="CD012723-sec-0061"> <h3 class="title" id="CD012723-sec-0061">Effects of interventions</h3> <p>See: <a href="./full#CD012723-tbl-0001"><b>Summary of findings 1</b> Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0002"><b>Summary of findings 2</b> Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0003"><b>Summary of findings 3</b> Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0004"><b>Summary of findings 4</b> Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0005"><b>Summary of findings 5</b> Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0006"><b>Summary of findings 6</b> Foam compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0007"><b>Summary of findings 7</b> Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0008"><b>Summary of findings 8</b> Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins</a>; <a href="./full#CD012723-tbl-0009"><b>Summary of findings 9</b> Sclerotherapy (hypertonic glucose plus polidocanol) compared to sclerotherapy (hypertonic glucose)</a>; <a href="./full#CD012723-tbl-0010"><b>Summary of findings 10</b> Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins</a> </p> <section id="CD012723-sec-0062"> <h4 class="title">Sclerotherapy (any sclerosing agent) versus placebo</h4> <p>Four studies compared sclerotherapy versus placebo (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). The sclerosing agents used in these four studies were: polidocanol; sodium tetradecyl sulfate (STS); hypertonic saline. We were able to pool the data for these four studies in meta‐analysis. <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a> was a split‐body study and the data were reported by procedure. See <a href="./full#CD012723-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012723-sec-0063"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>All four included studies showed improvement or resolution of telangiectasias individually, and this benefit from sclerotherapy was also seen on pooling the data (SMD 3.08, 95% CI 2.68 to 3.48; I<sup>2</sup> = 51%; 613 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0004" title="">Analysis 1.1</a>). We used a random‐effects model because of the clinical heterogeneity due to different agents used. </p> </section> <section id="CD012723-sec-0064"> <h5 class="title">Adverse events</h5> <p>Adverse events were studied in three of the included studies (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). Results showed that hyperpigmentation was more frequent in the group of sclerosing agents compared to the placebo group (RR 11.88, 95% CI 4.54 to 31.09; I<sup>2</sup> = 0%; 528 participants/procedures; moderate‐certainty evidence). Matting was more frequent in the group of sclerosing agents compared to the placebo group (RR 4.06, 95% CI 1.28 to 12.84; I<sup>2</sup> = 0%; 528 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0005" title="">Analysis 1.2</a>). </p> <p>Studies did not report on bruising, anaphylaxis or necrosis of the skin.</p> </section> <section id="CD012723-sec-0065"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>Only <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a> assessed the outcome pain. There was more pain experienced in the sclerotherapy group compared to the placebo group (SMD 0.70, 95% CI 0.06 to 1.34; 40 procedure; low‐certainty evidence) (<a href="./references#CD012723-fig-0006" title="">Analysis 1.3</a>). </p> <p>The outcomes 'recurrence', 'time to resolution' and 'quality of life (QoL)' were not reported by any of the four studies in this comparison. </p> </section> </section> <section id="CD012723-sec-0066"> <h4 class="title">Sclerotherapy (polidocanol) versus any sclerosing agent</h4> <p>Seven studies compared polidocanol versus another sclerosing agent (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>). Polidocanol was compared to STS (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>), to chromated glycerin (<a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>), and to hypertonic saline (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>). One study compared different concentrations of polidocanol without a control group (<a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a>). All included studies were split‐body studies and the data were reported by procedure, except for <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>, who reported by participant. See <a href="./full#CD012723-tbl-0002">summary of findings Table 2</a>. </p> <section id="CD012723-sec-0067"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>We found no clear difference between the polidocanol group compared to the group of other sclerosing agents, for improvement or resolution (SMD 0.01, 95% CI −0.13 to 0.14; I<sup>2</sup> = 0%; 7 studies, 852 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0007" title="">Analysis 2.1</a>). </p> </section> <section id="CD012723-sec-0068"> <h5 class="title">Adverse events</h5> <p>There was no clear difference between the polidocanol group and other sclerosing‐agent groups in cases of hyperpigmentation (RR 0.94, 95% CI 0.62 to 1.43; I<sup>2</sup> = 84%; 6 studies, 819 participants; moderate‐certainty evidence), or matting (RR 0.82, 95% CI 0.52 to 1.27; I<sup>2</sup> = 21%; 7 studies, 859 participants/procedures; moderate‐certainty evidence). There were no clear differences in bruising (RR 0.77, 95% CI 0.56 to 1.06; I<sup>2</sup> = 72%; 4 studies, 558 participants/procedures), microthrombosis (RR 0.96, 95% CI 0.69 to 1.34; I<sup>2</sup> = 0%; 4 studies, 394 participants/procedures); or allergy between the groups (RR 0.68, 95% CI 0.23 to 2.01; I<sup>2</sup> = 20%; 4 studies, 472 participants/procedures). There was less necrosis in the polidocanol group compared to the other sclerosing agents group (RR 0.07, 95% CI 0.02 to 0.29; I<sup>2</sup> = 0%; 4 studies, 558 participants) (<a href="./references#CD012723-fig-0008" title="">Analysis 2.2</a>). </p> </section> <section id="CD012723-sec-0069"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>There was less pain in the polidocanol group compared to other sclerosing agent group (SMD −0.26, 95% CI −0.44 to −0.08; I<sup>2</sup> = 0%; 5 studies, 480 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0009" title="">Analysis 2.3</a>). </p> <p>The outcomes 'recurrence', 'time to resolution' and 'QoL' were not available in the seven studies in this comparison. </p> </section> </section> <section id="CD012723-sec-0070"> <h4 class="title">Sclerotherapy (sodium tetradecyl sulfate (STS)) versus any sclerosing agent</h4> <p>Six studies compared sclerotherapy (sodium tetradecyl sulfate (STS)) with another sclerosing agent (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>). Sodium tetradecyl sulphate (STS) was compared to polidocanol (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0008" title="GoldmanMP . Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery2002;28(1):52-5. [PMID: 11991271]">Goldman 2002</a>; <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a>), to chromated glycerin (<a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>) and to hypertonic dextrose (<a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>). <a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>; <a href="./references#CD012723-bbs2-0031" title="PrescottRJ . A comparative study of two sclerosing agents in the treatment of telangiectasias. In: Phlebology '92. Vol. 2. Paris: John Libbey Eurotext, 1992:803-4. ">Prescott 1992</a>; <a href="./references#CD012723-bbs2-0033" title="RaoJ , WildemoreJK , GoldmanMP . Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery2005;31(6):631-5; discussion 635. [PMID: 15996411]">Rao 2005</a> were split‐body studies and the data were reported by procedure. See <a href="./full#CD012723-tbl-0003">summary of findings Table 3</a>. </p> <section id="CD012723-sec-0071"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was no clear difference in improvement or resolution between the STS group or other agents group (SMD −0.07, 95% CI −0.25 to 0.11; I<sup>2</sup> = 0%; 4 studies, 473 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0010" title="">Analysis 3.1</a>). </p> </section> <section id="CD012723-sec-0072"> <h5 class="title">Adverse events</h5> <p>There were more cases of hyperpigmentation (RR 1.71, 95% CI 1.10 to 2.64; ; I<sup>2</sup> = 65%; 4 studies, 478 participants/procedures; moderate‐certainty evidence), and matting (RR 2.10, 95% CI 1.14 to 3.85; I<sup>2</sup> = 0%; 2 studies, 323 participants; moderate‐certainty evidence) in the STS group compared with the other sclerosing agents group. There was more bruising (RR 1.62, 95% CI 1.14 to 2.30; I<sup>2</sup> = 53%; 3 studies, 418 participants/procedures) and necrosis (RR 16.31, 95% CI 3.14 to 84.79; I<sup>2</sup> = 0%; 2 studies, 392 participants/procedures) in the STS group. There was little or no difference in reports of allergy (RR 1.38, 95% CI 1.01 to 1.88; I<sup>2</sup> = 0%; 3 studies, 452 participants/procedures) or microthrombosis (RR 1.04, 95% CI 0.78 to 1.39; 1 study, 129 participants/procedures) (<a href="./references#CD012723-fig-0011" title="">Analysis 3.2</a>). </p> </section> <section id="CD012723-sec-0073"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>STS probably results in more pain compared with other sclerosing agents (RR 1.49, 95% CI 0.99 to 2.25; I<sup>2</sup> = 45%; 4 studies, 409 participants; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0012" title="">Analysis 3.3</a>). </p> <p>The outcomes 'recurrence', 'time to resolution' and 'QoL' were not reported in the six studies in this comparison. </p> </section> </section> <section id="CD012723-sec-0074"> <h4 class="title">Sclerotherapy (hypertonic saline) versus any sclerosing agent</h4> <p>We included three studies in this comparison (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>). The sclerosing agent hypertonic saline was compared to STS (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>) and to polidocanol (<a href="./references#CD012723-bbs2-0006" title="CarlinMC , RatzJL . Treatment of telangiectasia: comparison of sclerosing agents. Journal of Dermatologic Surgery and Oncology1987;13(11):1181-4. [PMID: 3312331]">Carlin 1987</a>; <a href="./references#CD012723-bbs2-0020" title="McCoyS , EvansA , SpurrierN . Sclerotherapy for leg telangiectasia - a blinded comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery1999;25(5):381-5; discussion 385-6. [PMID: 10469077]">McCoy 1999</a>; <a href="./references#CD012723-bbs2-0030" title="PetersonJD , GoldmanMP , WeissRA , DuffyDM , FabiSG , WeissMA , et al. Treatment of reticular and telangiectatic leg veins: double-blind, prospective comparative trial of polidocanol and hypertonic saline. Dermatologic Surgery2012;38(8):1322-30. [PMID: 22620717]">Peterson 2012b</a>). All included studies were split‐body studies and the data were reported by procedure. See <a href="./full#CD012723-tbl-0004">summary of findings Table 4</a>. </p> <section id="CD012723-sec-0075"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was no clear difference in improvement or resolution of telangiectasias between the hypertonic saline group and the other sclerosing agent group (SMD 0.01, 95% CI −0.20 to 0.22; I<sup>2</sup> = 0%; 3 studies, 348 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0013" title="">Analysis 4.1</a>). </p> </section> <section id="CD012723-sec-0076"> <h5 class="title">Adverse events</h5> <p>There were fewer cases of hyperpigmentation in the hypertonic saline group than in another‐sclerosing‐agent group or the polidocanol subgroup (RR 0.74, 95% CI 0.59 to 0.93; I<sup>2</sup> = 0%; 2 studies, 288 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0014" title="">Analysis 4.2</a>). </p> <p>There was no clear difference in matting between the hypertonic‐saline group and another‐sclerosing‐agent group (RR 0.89, 95% CI 0.58 to 1.36; 2 studies; I<sup>2</sup> = 0%; 288 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0014" title="">Analysis 4.2</a>). </p> <p>No other adverse effects have been reported in the included studies.</p> </section> <section id="CD012723-sec-0077"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>More pain was reported in the hypertonic‐saline group than in another‐sclerosing‐agent group (SMD 6.22, 95% CI 5.70 to 6.73; I<sup>2</sup> = 0%; 3 studies, 348 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0015" title="">Analysis 4.3</a>). </p> <p>The outcomes 'recurrence', 'time to resolution' and 'QoL' were not reported in the three studies in this comparison. </p> </section> </section> <section id="CD012723-sec-0078"> <h4 class="title">Sclerotherapy (chromated glycerin) versus any sclerosing agent</h4> <p>Four studies used chromated glycerin (<a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>; <a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>; <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>). Two studies analysed chromated glycerin as a sclerosing agent and compared it with POL (<a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>) and STS (<a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a>). <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a> and <a href="./references#CD012723-bbs2-0018" title="LeachBC , GoldmanMP . Comparative trial between sodium tetradecyl sulfate and glycerin in the treatment of telangiectatic leg veins. Dermatologic Surgery2003;29(6):612-5. [PMID: 12786704]">Leach 2003</a> were both split‐body studies and the data were reported by procedure. See <a href="./full#CD012723-tbl-0005">summary of findings Table 5</a>. </p> <p>The two further studies compared chromated glycerin versus chromated glycerin with different techniques, and assessed only pain, and so were not part of the meta‐analysis (<a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a>; <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a>). </p> <section id="CD012723-sec-0079"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was no difference in improvement or resolution of telangiectasias in the chromated glycerin group compared to the other sclerosing agent group (SMD 0.45, 95% CI −0.11 to 1.02; I<sup>2</sup> = 44%; 2 studies, 125 participants/procedures; low‐certainty evidence) (<a href="./references#CD012723-fig-0016" title="">Analysis 5.1</a>). </p> </section> <section id="CD012723-sec-0080"> <h5 class="title">Adverse events</h5> <p>There were no clear differences in hyperpigmentation (RR 0.49, 95% CI 0.09 to 2.50; I<sup>2</sup> = 0%; 2 studies, 125 participants/procedures; low‐certainty evidence), or matting (RR 0.31, 95% CI 0.01 to 7.53; 1 study, 99 participants/procedures; low‐certainty evidence) between the chromated‐glycerin group compared to the other‐sclerosing‐agent group. There were no differences in bruising (RR 0.14, 95% CI 0.02 to 1.00; 1 study, 26 participants/procedures) or microthrombosis (RR 1.32, 95% CI 0.45 to 3.87; 1 study, 99 participants/procedures) between analysed groups (<a href="./references#CD012723-fig-0017" title="">Analysis 5.2</a>). </p> </section> <section id="CD012723-sec-0081"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>There were no clear differences in pain (RR 1.50, 95% CI 0.30 to 7.55; 1 study, 26 participants/procedures; low‐certainty evidence) between the chromated glycerin group compared to another sclerosing agent (<a href="./references#CD012723-fig-0018" title="">Analysis 5.3</a>). </p> <p><a href="./references#CD012723-bbs2-0015" title="KernP , RameletAA , WutschertR , MazzolaiL . A double-blind, randomized study comparing pure chromated glycerin with chromated glycerin with 1% lidocaine and epinephrine for sclerotherapy of telangiectasias and reticular veins. Dermatologic Surgery2011;37(11):1590-4. [PMID: 21883648]">Kern 2011</a> studied pure chromated glycerin versus chromated glycerin plus 1% lidocaine, and demonstrated that a combination of chromated glycerin plus lidocaine resulted in less pain than chromated glycerin alone. <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a> studied conventional sclerotherapy with chromated glycerin versus sclerotherapy with chromated glycerin in two steps. <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a> concluded that the two‐step technique resulted in less pain than the conventional sclerotherapy technique. </p> <p>The outcomes 'recurrence', 'time to resolution' and 'QoL' were not available in the studies in this comparison. </p> </section> </section> <section id="CD012723-sec-0082"> <h4 class="title">Foam versus sclerotherapy (any sclerosant agent)</h4> <p>Foam was compared to polidocanol in three studies (<a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a>; <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>). </p> <p>We were able to pool data from two studies with 187 participants (<a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>; <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a>). <a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a> was a split‐body study and the data were reported by procedure. See <a href="./full#CD012723-tbl-0006">summary of findings Table 6</a>. </p> <section id="CD012723-sec-0083"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was no clear difference in improvement or resolution of telangiectasias between the foam group and the other‐sclerosing‐agents group (SMD 0.04, 95% CI −0.26 to 0.34; I<sup>2</sup> = 0%; 2 studies, 187 participants/procedures; low‐certainty evidence) (<a href="./references#CD012723-fig-0019" title="">Analysis 6.1</a>). </p> <p><a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a> studied 75 participants (150 procedures) comparing polidocanol and foam. Three months after treatment, total occlusion of the vein was observed in 94% of foam interventions and 54% of polidocanol interventions (P &lt; 0.001). Differences in the percentages of total efficacy for the two study groups were reported as statistically significant. </p> </section> <section id="CD012723-sec-0084"> <h5 class="title">Adverse events</h5> <p>There was no clear difference in hyperpigmentation between the foam group and the other‐sclerosing‐agents group (RR 2.12, 95% CI 0.44 to 10.23; I<sup>2</sup> = 0%; 2 studies, 187 participants/procedures; low‐certainty evidence). There were more cases of matting in the foam group compared with the other sclerosing agents group (RR 6.12, 95% CI 1.04 to 35.98; I<sup>2</sup> = 0%; 2 studies, 187 participants/procedures; low‐certainty evidence). There was no difference in bruising (RR 0.60, 95% CI 0.35 to 1.04; 1 study, 40 participants/procedures), or microthrombosis (RR 1.39, 95% CI 0.70 to 2.76; I<sup>2</sup> = 0%; 2 studies, 187 participants/procedures;) in the included studies (<a href="./references#CD012723-fig-0020" title="">Analysis 6.2</a>). </p> <p><a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a> reported that no complications occurred at the time of sclerotherapy. Inflammation was present in 25.3% of the foam group and 9.5% of the polidocanol liquid intervention group (P = 0.08). This study reported that the percentage of pigmentation was significantly higher at all follow‐up intervals for the foam group. </p> </section> <section id="CD012723-sec-0085"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>There was no clear difference in pain between the foam group compared to the other‐sclerosing‐agents group (SMD −0.10, 95% CI −0.44 to 0.24; 1 study, 147 participants/procedures; low‐certainty evidence) (<a href="./references#CD012723-fig-0021" title="">Analysis 6.3</a>). </p> <p><a href="./references#CD012723-bbs2-0003" title="BenigniJP , SadounS , ThirionV , SicaM , DemagnyA , ChahimM . Telangiectases and reticular veins treatment with a 0.25% aetoxisclerol foam. Presentation of a pilot study. Phlébologie1999;52(3):283-90. ">Benigni 1999</a>, <a href="./references#CD012723-bbs2-0013" title="KernP , RameletAA , WutschertR , BounameauxH , HayozD . Single-blind, randomized study comparing chromated glycerin, polidocanol solution, and polidocanol foam for treatment of telangiectatic leg veins. Dermatologic Surgery2004;30(3):367-72. [PMID: 15008862]">Kern 2004</a> and <a href="./references#CD012723-bbs2-0001" title="AlosJ , CarrenoP , LopezJA , EstadellaB , Serra-PratM , Marinel-LoJ . Efficacy and safety of sclerotherapy using polidocanol foam: a controlled clinical trial. European Journal of Vascular and Endovascular Surgery2006;31(1):101-7. [PMID: 16226901]">Alos 2006</a> did not report 'recurrence', 'time to resolution' or 'QoL'. </p> </section> </section> <section id="CD012723-sec-0086"> <h4 class="title">Laser versus sclerotherapy (any sclerosing agent)</h4> <p>Five studies were included in this comparison (<a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>). Laser was compared to STS (<a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>), hypertonic glucose, (<a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a>), and polidocanol (<a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a>; <a href="./references#CD012723-bbs2-0028" title="ParlarB , BlazekC , CazzanigaS , NaldiL , KloetgenHW , BorradoriL , et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. Journal of the European Academy of Dermatology and Venereology2015;29(3):549-54. [PMID: 25069999]">Parlar 2015</a>). <a href="./references#CD012723-bbs2-0011" title="IanosiG , IanosiS , Calbureanu-PopescuMX , TutunaruC , CalinaD , NeagoeD . Comparative study in leg telangiectasias treatment with Nd:YAG laser and sclerotherapy. Experimental and Therapeutic Medicine2019;17(2):1106-12. [PMID: 30679981]">Ianosi 2019</a>; <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a> and <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a> were split‐body studies and the data were reported by procedure. See <a href="./full#CD012723-tbl-0007">summary of findings Table 7</a>. </p> <section id="CD012723-sec-0087"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There were no clear differences in improvement or resolution of telangiectasias in the laser group compared to the any‐sclerosing‐agent group (SMD −0.09, 95% CI −0.25 to 0.07; I<sup>2</sup> = 0%; 5 studies, 593 participants/procedures;moderate‐certainty evidence) (<a href="./references#CD012723-fig-0022" title="">Analysis 7.1</a>). </p> </section> <section id="CD012723-sec-0088"> <h5 class="title">Adverse events</h5> <p>There were fewer hyperpigmentation events in the laser group than in the any‐sclerosing‐agent group (RR 0.57, 95% CI 0.40 to 0.80; I<sup>2</sup> = 0%; 4 studies, 262 participants/procedures; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0023" title="">Analysis 7.2</a>). </p> <p>There were no clear differences between the laser group compared to the any‐sclerosing‐agent group in matting (RR 1.00, 95% CI 0.46 to 2.19; I<sup>2</sup> = 0%; 2 studies, 162 participants/procedures;moderate‐certainty evidence). There were no differences in bruising (RR 0.79, 95% CI 0.60 to 1.04; 1 study, 40 participants/procedures), or necrosis (RR 1.60, 95% CI 0.20 to 12.74; I<sup>2</sup> = 0%; 3 studies, 202 participants/procedures) in the included studies (<a href="./references#CD012723-fig-0023" title="">Analysis 7.2</a>). </p> </section> <section id="CD012723-sec-0089"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>Due to the high heterogeneity among the included studies (I<sup>2</sup> = 94%), we present the results qualitatively (<a href="./references#CD012723-fig-0024" title="">Analysis 7.3</a>). </p> <p>In <a href="./references#CD012723-bbs2-0019" title="LuptonJR , AlsterTS , RomeroP . Clinical comparison of sclerotherapy versus long-pulsed Nd:YAG laser treatment for lower extremity telangiectases. Dermatologic Surgery2002;28(8):694-7. [PMID: 12174060]">Lupton 2002</a>, 70% of 20 participants reported mild treatment pain associated with both methods (laser and conventional sclerotherapy). <a href="./references#CD012723-bbs2-0023" title="MuniaMA , WoloskerN , MuniaCG , ChaoWS , Puech-LeaoP . Comparison of laser versus sclerotherapy in the treatment of lower extremity telangiectases: a prospective study. Dermatologic Surgery2012;38(4):635-9. [PMID: 22221551]">Munia 2012</a> reported mild treatment pain in 7/30 participants in the laser group versus 26/30 in the sclerotherapy group; very painful in 20/30 participants versus 4/30 participants respectively in laser and sclerotherapy groups; and extremely painful in 3/30 participants in the laser group versus 0/30 in the sclerotherapy group. </p> <p>The outcomes 'recurrence', 'time to resolution' and 'QoL' were not reported by the four studies in this comparison. </p> </section> </section> <section id="CD012723-sec-0090"> <h4 class="title">Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol)</h4> <p><a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a> and <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a> compared a combination technique with laser neodymium: YAG (Nd:YAG) plus polidocanol (foam) sclerotherapy versus only sclerotherapy with polidocanol (foam). See <a href="./full#CD012723-tbl-0008">summary of findings Table 8</a>. </p> <section id="CD012723-sec-0091"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was more improvement or resolution in telangiectasias and reticular veins in the laser‐plus‐sclerotherapy group compared to the sclerotherapy group (SMD 5.68, 95% CI 5.14 to 6.23; I<sup>2</sup> = 19%; 2 studies, 710 participants; low‐certainty evidence) (<a href="./references#CD012723-fig-0025" title="">Analysis 8.1</a>). </p> </section> <section id="CD012723-sec-0092"> <h5 class="title">Adverse events</h5> <p>There were no clear differences in hyperpigmentation (RR 0.83, 95% CI 0.35 to 1.99; I<sup>2</sup> = 0%; 2 studies, 656 participants; low‐certainty evidence), or matting (RR 0.83, 95% CI 0.21 to 3.28; I<sup>2</sup> = 0%; 2 studies, 656 participants; low‐certainty evidence) in the combination‐technique group compared to the sclerosing‐agent‐alone group. Studies did not report on bruising, anaphylaxis or necrosis of the skin (<a href="./references#CD012723-fig-0026" title="">Analysis 8.2</a>). </p> </section> <section id="CD012723-sec-0093"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>Only <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a> reported on pain. There was more pain in the combination‐technique group compared to the sclerosing‐agent‐alone group (RR 2.44, 95% CI 1.69 to 3.55; 1 study, 596 participants; low‐certainty evidence). </p> <p><a href="./references#CD012723-bbs2-0021" title="Moreno-MoragaJ , HernandezE , RoyoJ , AlcoleaJ , IsarriaMJ , PascuML , et al. Optimal and safe treatment of spider leg veins measuring less than 1.5 mm on skin type IV patients, using repeated low-fluence Nd:YAG laser pulses after polidocanol injection. Laser in Medical Science2013;28(3):925-33. ">Moreno‐Moraga 2013</a> and <a href="./references#CD012723-bbs2-0022" title="Moreno-MoragaJ , SmarandacheA , PascuML , RoyoJ , TrellesMA . 1064 nm Nd:YAG long pulse laser after polidocanol microfoam injection dramatically improves the result of leg vein treatment: a randomized controlled trial on 517 legs with a three-year follow-up. Phlebology2014;29(10):658-66. [PMID: 23989971]">Moreno‐Moraga 2014</a> did not report 'recurrence', 'time to resolution' or 'QoL'. </p> </section> </section> <section id="CD012723-sec-0094"> <h4 class="title">Sclerotherapy (hypertonic glucose plus polidocanol) versus hypertonic glucose</h4> <p>Two studies (191 participants) analysed hypertonic glucose as a sclerosing agent and compared hypertonic glucose plus polidocanol versus hypertonic glucose (<a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a>; <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a>). See <a href="./full#CD012723-tbl-0009">summary of findings Table 9</a>. </p> <section id="CD012723-sec-0095"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was more improvement or resolution of telangiectasias in the combination‐technique group (polidocanol plus hypertonic glucose) when compared with the hypertonic‐glucose group (SMD 0.79, 95% CI 0.50 to 1.09; I<sup>2</sup> = 0%; 2 studies, 191 participants; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0028" title="">Analysis 9.1</a>). </p> </section> <section id="CD012723-sec-0096"> <h5 class="title">Adverse events</h5> <p>There were no clear differences in hyperpigmentation (RR 0.79, 95% CI 0.62 to 1.01; I<sup>2</sup> = 0%; 2 studies, 191 participants; moderate‐certainty evidence); matting (RR 0.78, 95% CI 0.51 to 1.20; I<sup>2</sup> = 0%; 2 studies, 191 participants; moderate‐certainty evidence) when comparing the combination technique (polidocanol plus hypertonic glucose) with the hypertonic‐glucose group (<a href="./references#CD012723-fig-0029" title="">Analysis 9.2</a>). </p> <p>No other adverse events were reported.</p> </section> <section id="CD012723-sec-0097"> <h5 class="title">Pain during procedure and post‐procedure</h5> <p>There were no clear differences in pain (RR 1.02, 95% CI 0.83 to 1.24; I<sup>2</sup> = 0%; 2 studies, 191 participants; moderate‐certainty evidence), when comparing the combination‐technique group (polidocanol plus hypertonic glucose) with the hypertonic‐glucose group (<a href="./references#CD012723-fig-0030" title="">Analysis 9.3</a>). </p> <p><a href="./references#CD012723-bbs2-0004" title="BertanhaM , JaldinRG , MouraR , PimentaRE , MariubaJV , Lucio FilhoCE , et al. Sclerotherapy for reticular veins in the lower limbs: a triple-blind randomized clinical trial. JAMA Dermatology2017;153(12):1249-55. [PMID: 28973414]">Bertanha 2017</a> and <a href="./references#CD012723-bbs2-0005" title="BertanhaM , YoshidaWB , Bueno de CamargoPA , MouraR , Reis de PaulaD , PadovaniCR , et al. Polidocanol plus glucose versus glucose alone for the treatment of telangiectasias: triple blind, randomised controlled trial (PG3T). European Journal of Vascular and Endovascular Surgery2021;61(1):128-35. [PMID: 32778489]">Bertanha 2021</a> did not evaluate 'recurrence', 'time to resolution' or 'QoL'. </p> </section> </section> <section id="CD012723-sec-0098"> <h4 class="title">Compression after sclerotherapy</h4> <p><a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a> and <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a> studied the effect of compression after sclerotherapy. Both groups underwent sclerotherapy, then one group was randomised to go without compression stockings (WCS) and one group was randomised to use compression stocking (23 to 32 mmHg). </p> <section id="CD012723-sec-0099"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>There was no difference in improvement or resolution in the compression‐after‐sclerotherapy group compared to the WCS group (SMD 0.09, 95% CI −0.19 to 0.37; I<sup>2</sup> = 0%; 2 studies, 196 participants; moderate‐certainty evidence) (<a href="./references#CD012723-fig-0031" title="">Analysis 10.1</a>). </p> </section> <section id="CD012723-sec-0100"> <h5 class="title">Adverse events</h5> <p>There were no clear differences in adverse events between the compression‐after‐sclerotherapy group and the WCS group for hyperpigmentation (RR 0.93, 95% CI 0.41 to 2.07; ; I<sup>2</sup> = 0%; 2 studies, 196 participants; moderate‐certainty evidence); or matting (RR 1.84, 95% CI 0.17 to 19.62; 1 study, 96 participants; low‐certainty evidence) (<a href="./references#CD012723-fig-0032" title="">Analysis 10.2</a>). </p> </section> <section id="CD012723-sec-0101"> <h5 class="title">Quality of life (QoL)</h5> <p>There was no difference in QoL scores (SF‐36 questionnaires) between the compression‐after‐sclerotherapy group and the WCS group (SMD −0.02, 95% CI −0.42 to 0.39; 1 study, 93 participants; low‐certainty evidence) (<a href="./references#CD012723-fig-0033" title="">Analysis 10.3</a>). </p> <p>The outcomes 'pain', 'recurrence' and 'time to resolution' were not reported by <a href="./references#CD012723-bbs2-0014" title="KernP , RameletAA , WutschertR , HayozD . Compression after sclerotherapy for telangiectasias and reticular leg veins: a randomized controlled study. Journal of Vascular Surgery2007;45(6):1212-6. [PMID: 17467226]">Kern 2007</a> or <a href="./references#CD012723-bbs2-0002" title="BayerA , KuznikN , LanganEA , ReckeA , ReckeAL , FaerberG , et al. Clinical outcome of short-term compression after sclerotherapy for telangiectatic varicose veins. Journal of Vascular Surgery2021;9(2):435-43. [PMID: 32502730]">Bayer 2021</a>. </p> </section> </section> <section id="CD012723-sec-0102"> <h4 class="title">Foam (STS plus air) versus foam (STS plus CO<sub>2</sub>) </h4> <p>Only <a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a> studied different types of foam combined with air or CO<sub>2</sub>. </p> <section id="CD012723-sec-0103"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p><a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a> reported no difference in improvement or resolution in reticular veins when the STS‐plus‐air group (20 participants) was compared with the STS‐plus‐CO<sub>2</sub> group (20 participants). The study authors did not explore the resolution of telangiectasias, since these veins were treated with glycerin solution. </p> </section> <section id="CD012723-sec-0104"> <h5 class="title">Adverse events</h5> <p><a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a> reported there was no clear difference in adverse events between the STS‐plus‐air group and the STS‐plus‐CO<sub>2</sub> group. Coagulums were presented in 55% of CO<sub>2</sub> foam and 60% of RA foam (P = 0.75). </p> <p><a href="./references#CD012723-bbs2-0029" title="PetersonJD , GoldmanMP . An investigation of side-effects and efficacy of foam-based sclerotherapy with carbon dioxide or room air in the treatment of reticular leg veins: a pilot study. Phlebology2012;27(2):73-6. [PMID: 21926097]">Peterson 2012a</a> did not report 'pain', 'recurrence', 'time to resolution' or 'QoL'. </p> </section> </section> <section id="CD012723-sec-0105"> <h4 class="title">Foam (POL plus 1:2 air) versus foam (POL plus 1:4 air)</h4> <p>Only <a href="./references#CD012723-bbs2-0010" title="HossE , KolliparaR , BoenM , AlhaddadM , GoldmanMP . Comparison of the safety and efficacy of foam sclerotherapy with 1: 2 polidocanol to air ratio versus 1: 4 ratio for the treatment of reticular veins of the lower extremities. Dermatologic Surgery2020;46(12):1715-20. [PMID: 32947299]">Hoss 2020</a> studied foam with polidocanol combined with different proportions of air (1:2 and 1:4). </p> <section id="CD012723-sec-0106"> <h5 class="title">Resolution or improvement of telangiectasias</h5> <p>The study authors reported a mean improvement between 0% and 50% at day 21 and 26% to 75% at day 90, with no significant difference in the resolution or improvement of the reticular veins between the 1:2 ratio versus the 1:4 ratio groups. </p> </section> <section id="CD012723-sec-0107"> <h5 class="title">Adverse events</h5> <p>The study authors found no statistically significant difference for adverse events between the 1:2 and 1:4 ratio groups at any time point. Most participants rated pain during injection (1.73 vs 1.70), current pain (0.80 vs 1.07), itching (0.57 vs 0.83), swelling (0.93 vs 1.37), and redness (1.53 vs 1.83) as none, minimal, or mild in both the 1:2 and 1:4 ratio groups, respectively. </p> </section> </section> <section id="CD012723-sec-0108"> <h4 class="title">Laser versus laser</h4> <p>We included four studies for a qualitative analysis (<a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>; <a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a>; <a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a>; <a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a>). We did not pool data in a meta‐analysis because they were isolated studies using different laser techniques that cannot be pooled. </p> <p><a href="./references#CD012723-bbs2-0027" title="OzdenMG , BahcivanM , AydinF , SenturkN , BekY , CanturkT , et al. Clinical comparison of potassium-titanyl-phosphate (KTP) versus neodymium:YAG (Nd:YAG) laser treatment for lower extremity telangiectases. Journal of Dermatological Treatment2011;22(3):162-6. [PMID: 20666669]">Ozden 2011</a> studied potassium‐titanyl‐phosphate (KTP) versus Nd:YAG. </p> <p>Study authors reported a significant positive correlation in the Nd:YAG group compared to the KTP laser group for outcome improvement or resolution in veins of 1.0 mm to 3.0 mm. There was no difference between KTP and Nd:YAG laser for telangiectasias and veins of less than 1.0 mm. They reported that both laser treatments were well‐tolerated by all participants, with no reported serious adverse events. Urticaria appeared in most participants immediately after treatment, but resolved within a few hours. The average level of pain reported by participants during treatment with the KTP laser was 3.1 (95% CI 2.23 to 3.97) compared with 6.89 (95% CI 5.63 to 8.15) for the Nd:YAG treatment. </p> <p><a href="./references#CD012723-bbs2-0017" title="KleinA , BuschmannM , BabilasP , LandthalerM , BaumlerW . Indocyanine green-augmented diode laser therapy vs. long-pulsed Nd:YAG (1064 nm) laser treatment of telangiectatic leg veins: a randomized controlled trial. British Journal of Dermatology2013;169(2):365-73. [PMID: 23646932]">Klein 2013</a> studied indocyanine green (ICG)‐augmented diode laser therapy (808 nm) versus diode laser without ICG and pulsed dye laser (PDL). </p> <p>The mean clearance rate of resolution of telangiectasias for PDL therapy after three months was 2.07 (95% CI 1.07 to 3.07) (moderate clearance), as rated by the participants, and 0.78 (95% CI −0.11 to 1.67) (no difference) as rated by the blinded investigator. The rate of resolution of telangiectasias for ICG diode laser therapy alone was 0.3, as rated by the blinded investigator. Hypopigmentation and hyperpigmentation were seen in 32% of participants. </p> <p><a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a> studied different parameters of Nd:YAG laser. The application of Nd;YAG laser with fixed (FF) and adjustable (JF) parameters has been studied. There was no difference in improvement or resolution with FF or JF parameters. </p> <p>There was a higher incidence of adverse events (hyperpigmentation) at 39.3% versus 28.6% in the FF group (P = 0.05). </p> <p>Pain was not mentioned by <a href="./references#CD012723-bbs2-0007" title="ChristiansenK , DrosnerM , BjerringP . Optimized settings for Nd:YAG laser treatments of leg telangiectasias. Journal of Cosmetic and Laser Therapy2015;17(2):69-76. [PMID: 25415373]">Christiansen 2015</a>. </p> <p><a href="./references#CD012723-bbs2-0024" title="NguyenHT , FirasAN , VanTT . Long-pulsed 1064-nm and 755-nm lasers for C1 leg veins on skin type IV patients: a side-by-side comparison. Lasers in Medical Science2020;36(4):829-35. [PMID: 32748167]">Nguyen 2020</a> studied long pulsed 1064 nm (LP 1064) versus 755 nm (LP 755). There was no difference in improvement or resolution of telangiectasias or reticular veins (71.87% in LP 1064 versus 71.69% in LP 755, P = 0.99). All participants reported painful sensation. The study reported that pain caused by LP 1064 with a median of 7 (range 2 to 8) was significantly higher than pain caused by LP 755, with a median of 5 (range 2 to 8; P = 0.001). Hyperpigmentation occurred in half or more of the participants at one month of observation, with no significant difference between the two groups (63.64% and 50% for LP 1064 and LP 755, respectively; P = 0.36). </p> <p>The preplanned outcomes 'recurrence', 'time to resolution' and 'QoL' were not reported by the studies in this comparison. </p> </section> <section id="CD012723-sec-0109"> <h4 class="title">Different concentrations of polidocanol</h4> <p><a href="./references#CD012723-bbs2-0025" title="NorrisMJ , CarlinMC , RatzJL . Treatment of essential telangiectasia: effects of increasing concentrations of polidocanol. Journal of the American Academy of Dermatology1989;20(4):643-9. [PMID: 2654207]">Norris 1989</a> compared different concentrations of polidocanol, 0.25%, 0.50%, 0.75%, and 1.0% in 20 participants. There were no differences among the four dosages for improvement or resolution of telangiectasias, itching, or neovascularisation. Polidocanol concentrations of 0.75% and 1% showed more hyperpigmentation (P = 0.15 and P = 0.07, respectively). </p> </section> <section id="CD012723-sec-0110"> <h4 class="title">Compression versus sclerotherapy</h4> <p><a href="./references#CD012723-bbs2-0034" title="SchulMW , EatonT , EdmanB . Compression versus sclerotherapy for patients with isolated refluxing reticular veins and telangiectasia: a randomized trial comparing quality-of-life outcomes. Phebology2011;26(4):148-156. ">Schul 2011</a> compared compression stockings (20 to 30 mmHg) versus sclerotherapy in 58 participants with symptomatic reticular veins and telangiectasias. They only reported on quality of life, measured using an Aberdeen Varicose Vein Questionnaire. The study reported that compression stockings can offer relief of aching (P &lt; 0.001), pain (P = 0.002); and cramping (P = 0.003) in participants with isolated refluxing reticular veins and telangiectasias. Sclerotherapy of these smaller vessels offers superior relief of aching (P &lt; 0.001), pain (P &lt; 0.001), swelling (P &lt; 0.001), leg cramps (P &lt; 0.05), and presence of symptoms at rest. </p> </section> <section id="CD012723-sec-0111"> <h4 class="title">Sclerotherapy plus sulodexide versus sclerotherapy</h4> <p><a href="./references#CD012723-bbs2-0026" title="OchoaAJ , CarrilloJ , ManríquezD , ManriqueF , VazquezAN . Reducing hyperpigmentation after sclerotherapy: a randomized clinical trial. Journal of Vascular Surgery2021;9(1):154-62. [PMID: 32739509]">Ochoa 2021</a> compared sclerotherapy with POL plus sulodexide versus sclerotherapy in 609 participants with telangiectasias and reticular veins. The study authors reported there was no difference in improvement or resolution between sulodexide group and control group after three months (76% in sulodexide group and 73% in control group, P = 0.61). There was less hyperpigmentation in the sulodexide group compared with the control group at one month (10.7% in sulodexide group and 18.2% control group; P &lt; 0.01). </p> </section> <section id="CD012723-sec-0112"> <h4 class="title">Sclerotherapy plus warfarin versus sclerotherapy plus nadroparin</h4> <p><a href="./references#CD012723-bbs2-0009" title="Hameo-DesnosCM , GilletJL , DesnosPR , AllaertFA . Sclerotherapy of varicose veins in patients with documented thrombophilia: a prospective controlled randomized study of 105 cases. Phebology2009;24(4):176-82. ">Hamel‐Desnos 2009</a> compared sclerotherapy with POL plus warfarin versus sclerotherapy with POL plus nadroparin in 105 participants with thrombophilia. There was no thromboembolic event in any group. The rate of inflammatory reactions (1.5%) and superficial thrombophlebitis (1.5%) did not exceed that found in the general population (4.5%). They did not report on any other outcomes of interest. </p> </section> <section id="CD012723-sec-0113"> <h4 class="title">Reporting bias, subgroup and sensitivity analyses</h4> <p>We were unable to assess reporting bias using funnel plots, as none of the meta‐analyses included 10 or more studies. </p> <p>We were unable to perform the planned subgroup analyses for interventions of participant characteristics, because there were no data available in the selected studies. </p> <p>We planned to carry out sensitivity analyses by excluding those trials that we judged to be at high risk of bias for allocation concealment or blinding of outcome assessment. No studies were at high risk of allocation bias. <a href="./references#CD012723-bbs2-0016" title="KernP . Sclerotherapy of telangiectasias: a painless two-step technique. Dermatologic Surgery2012;38(6):860-4. [PMID: 22404250]">Kern 2012</a> was at high risk from blinding of outcome assessment, but was not included in any meta‐analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012723-sec-0114" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012723-sec-0114"></div> <section id="CD012723-sec-0115"> <h3 class="title" id="CD012723-sec-0115">Summary of main results</h3> <p>We identified 35 randomised controlled trials (RCTs) with a total of 3632 participants, which used a variety of different methods to treat telangiectasias and reticular veins. None of the included studies reported on recurrence or time to resolution, and most did not report on quality of life (QoL). </p> <p>There is moderate‐certainty evidence that sclerosing agents are more effective for resolution or improvement of telangiectasias compared to a placebo, but that they also have more adverse effects. The observed adverse effects were relatively minor, such as hyperpigmentation and matting. There may be increased pain caused by the sclerosing agent that cannot be attributed solely to the injection of the agent (low‐certainty evidence). See <a href="./full#CD012723-tbl-0001">summary of findings Table 1</a>. </p> <p>We did not find reliable evidence for the superiority of any of the various sclerosing agents studied for resolution or improvement of telangiectasias (moderate‐certainty evidence). See <a href="./full#CD012723-tbl-0002">summary of findings Table 2</a>. Polidocanol and hypertonic saline probably cause less necrosis and hyperpigmentation respectively, when compared to other sclerosing agents (moderate‐certainty evidence). STS resulted in more hyperpigmentation, matting (moderate‐certainty evidence), bruising and necrosis, and probably more pain(moderate‐certainty evidence), than the other sclerosing agents. See <a href="./full#CD012723-tbl-0003">summary of findings Table 3</a>. Hypertonic saline may result in more pain compared to other sclerosing agents (moderate‐certainty evidence). See <a href="./full#CD012723-tbl-0004">summary of findings Table 4</a>. There were few studies with glycerin and glucose and no differences in resolution or improvement of telangiectasias, adverse events or pain were detected (low‐certainty evidence). See <a href="./full#CD012723-tbl-0005">summary of findings Table 5</a>. </p> <p>The use of foam did not affect resolution compared to liquid polidocanol (low‐certainty evidence), and no clear differences were detected in hyperpigmentation, bruising, microthrombus or pain (low‐certainty evidence). There may be more matting in the foam group compared to other sclerosing agents (low‐certainty evidence). See <a href="./full#CD012723-tbl-0006">summary of findings Table 6</a>. </p> <p>Laser treatment had similar improvement or resolution of telangiectasias compared to the any‐sclerosing‐agent group (moderate‐certainty evidence). Laser treatment may result in less hyperpigmentation compared to any sclerosing agents (moderate‐certainty evidence), but no differences were detected for matting, bruising or necrosis compared to other sclerosing agents. Due to the high heterogeneity among the included studies, the pain data are presented qualitatively. See <a href="./full#CD012723-tbl-0007">summary of findings Table 7</a>. </p> <p>The combination technique laser plus polidocanol may be more effective to treat telangiectasias and reticular veins compared to polidocanol alone (low‐certainty evidence). There were no differences in hyperpigmentation and matting (low‐certainty evidence), but more pain may occur after laser plus polidocanol (low‐certainty evidence). See <a href="./full#CD012723-tbl-0008">summary of findings Table 8</a>. </p> <p>The combination technique hypertonic glucose plus polidocanol was probably more effective to treat telangiectasias and reticular veins compared to hypertonic glucose alone (moderate‐certainty evidence). There were no differences in hyperpigmentation, matting or pain (moderate‐certainty evidence). See <a href="./full#CD012723-tbl-0009">summary of findings Table 9</a>. </p> <p>The combination technique sclerotherapy plus compression did not affect improvement or resolution of telangiectasias compared to sclerotherapy alone (moderate‐certainty evidence). No clear differences were detected for hyperpigmentation (moderate‐certainty evidence), matting or QoL (low‐certainty evidence). See <a href="./full#CD012723-tbl-0010">summary of findings Table 10</a>. </p> </section> <section id="CD012723-sec-0116"> <h3 class="title" id="CD012723-sec-0116">Overall completeness and applicability of evidence</h3> <p>We did not find any studies comparing intensive pulsed light (IPL), thermocoagulation and microphlebectomy with other techniques for treatment of telangiectasias and reticular veins. The included studies did not present data on time to resolution, recurrence or QoL. We found different study designs using either body parts (opposite leg or a lower limb quadrant), or the individual participant as a research unit, which makes it difficult to analyse the data together. </p> </section> <section id="CD012723-sec-0117"> <h3 class="title" id="CD012723-sec-0117">Quality of the evidence</h3> <p>We used GRADE to evaluate the certainty of the evidence (<a href="./references#CD012723-bbs2-0056" title="AtkinsD , BestD , BrissPA , EcclesM , Falck-YtterY , FlottorpS , et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490.">Grade 2004</a>). </p> <section id="CD012723-sec-0118"> <h4 class="title">Sclerotherapy versus placebo</h4> <p>See <a href="./full#CD012723-tbl-0001">summary of findings Table 1</a>. The certainty of the evidence for the outcome 'resolution or improvement of telangiectasias' was downgraded by one level to moderate because of inconsistency due to the clinical heterogeneity of the included studies. We downgraded by one level to moderate for adverse events (hyperpigmentation and matting) because of clinical heterogeneity and imprecision due to the wide of confidence intervals (CIs). The certainty of the evidence for pain was downgraded by two levels to low because of clinical heterogeneity, the small sample size and the data being from a single study. </p> </section> <section id="CD012723-sec-0119"> <h4 class="title">Polidocanol versus any sclerosing agent</h4> <p>See <a href="./full#CD012723-tbl-0002">summary of findings Table 2</a>. The certainty of the evidence for the outcomes 'resolution or improvement of telangiectasias', adverse events (hyperpigmentation and matting), and pain was downgraded by one level due to a wide CI. </p> </section> <section id="CD012723-sec-0120"> <h4 class="title">STS versus any sclerosing agent</h4> <p>See <a href="./full#CD012723-tbl-0003">summary of findings Table 3</a>. The certainty of the evidence for the outcomes 'resolution or improvement of telangiectasias', adverse events (hyperpigmentation and matting), and pain was downgraded by one level to moderate because of imprecision, due to the wide CI and few included participants. </p> </section> <section id="CD012723-sec-0121"> <h4 class="title">Hypertonic saline versus any sclerosing agent</h4> <p>See <a href="./full#CD012723-tbl-0004">summary of findings Table 4</a>. The certainty of the evidence for the outcome 'resolution or improvement of telangiectasias' was downgraded by one level to moderate because of risk of bias in the included studies. The certainty of the evidence for adverse events (hyperpigmentation and matting) was downgraded by one level to moderate because of imprecision due to the wide CI. Pain was downgraded by one level to moderate due to the clinical heterogeneity of the included studies. </p> </section> <section id="CD012723-sec-0122"> <h4 class="title">Chromated glycerin versus any sclerosing agent</h4> <p>See <a href="./full#CD012723-tbl-0005">summary of findings Table 5</a>. The certainty of the evidence for the outcomes 'resolution or improvement of telangiectasias', adverse events (hyperpigmentation, matting) and pain, was downgraded by two levels to low because of few included participants. </p> </section> <section id="CD012723-sec-0123"> <h4 class="title">Foam versus any sclerosing agent</h4> <p>See <a href="./full#CD012723-tbl-0006">summary of findings Table 6</a>. The certainty of the evidence for the outcomes 'resolution or improvement of telangiectasias', adverse events (hyperpigmentation and matting), and pain was downgraded by two levels to low because of imprecision, due to the wide CI and few participants in the included studies. </p> </section> <section id="CD012723-sec-0124"> <h4 class="title">Laser versus sclerotherapy</h4> <p>See <a href="./full#CD012723-tbl-0007">summary of findings Table 7</a>. The certainty of the evidence for the outcome 'resolution or improvement of telangiectasias', adverse events (hyperpigmentation and matting) was downgraded by one level to moderate because of imprecision due to the wide CI. Pain was downgraded by two levels because of few participants in the included studies. </p> </section> <section id="CD012723-sec-0125"> <h4 class="title">Laser plus POL versus POL</h4> <p>See <a href="./full#CD012723-tbl-0008">summary of findings Table 8</a>. The certainty of the evidence for the outcome 'resolution or improvement of telangiectasias', and adverse events (hyperpigmentation and matting), was downgraded by two levels to low because of inconsistency due to the clinical heterogeneity between the included studies and the fact that the two studies in this comparison were conducted by the same group of investigators. Pain was downgraded by two levels to low because there was only one included study. </p> </section> <section id="CD012723-sec-0126"> <h4 class="title">Hypertonic glucose plus POL versus hypertonic glucose</h4> <p>See <a href="./full#CD012723-tbl-0009">summary of findings Table 9</a>. The certainty of the evidence for all outcomes,'resolution or improvement of telangiectasias', adverse events (hyperpigmentation and matting) and pain was downgraded by one level to moderate because of few participants in the included studies. </p> </section> <section id="CD012723-sec-0127"> <h4 class="title">Sclerotherapy plus compression versus sclerotherapy</h4> <p>See <a href="./full#CD012723-tbl-0010">summary of findings Table 10</a>. The certainty of the evidence for 'resolution or improvement of telangiectasias' and hyperpigmentation was downgraded by one level to moderate because of few participants in the included studies. Matting and QoL were downgraded two levels because of few participants and only one included study. </p> </section> </section> <section id="CD012723-sec-0128"> <h3 class="title" id="CD012723-sec-0128">Potential biases in the review process</h3> <p>We have attempted to include all available RCTs in this review, but it is possible that some studies have not been included, especially from the grey literature. We adhered to the inclusion and exclusion criteria prespecified in the protocol in order to limit subjectivity (<a href="./references#CD012723-bbs2-0089" title="NakanoLC , CacioneDG , Baptista-SilvaJC , FlumignanRL . Treatment for telangiectasias and reticular veins. Cochrane Database of Systematic Reviews2017, Issue 7. Art. No: CD012723. [DOI: 10.1002/14651858.CD012723]">Nakano 2017</a>). We made efforts to obtain additional relevant data from study authors but were unable to do so for all. If we can source supplementary data, we will consider them in future updates. Two review authors selected studies in duplicate, independently, to reduce potential bias of the review process. Three review authors independently extracted and collected data, and assessed risks of bias of the included studies to reduce potential bias in the review process. We were not able to include all studies in a meta‐analysis. </p> </section> <section id="CD012723-sec-0129"> <h3 class="title" id="CD012723-sec-0129">Agreements and disagreements with other studies or reviews</h3> <p><a href="./references#CD012723-bbs2-0075" title="SchwartzL , MaxwellH . Sclerotherapy for lower limb telangiectasias. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD008826. [DOI: 10.1002/14651858.CD008826.pub2] [PMID: 22161437]">Schwartz 2011</a> studied sclerosing agents for the treatment of telangiectasias, but they evaluated neither reticular veins nor adverse events in their review. In agreement with our findings, <a href="./references#CD012723-bbs2-0075" title="SchwartzL , MaxwellH . Sclerotherapy for lower limb telangiectasias. Cochrane Database of Systematic Reviews2011, Issue 12. Art. No: CD008826. [DOI: 10.1002/14651858.CD008826.pub2] [PMID: 22161437]">Schwartz 2011</a> reported that no sclerosing agent studied was more effective than the others, with a low quality of evidence due to a lack of eligible studies. </p> <p><a href="./references#CD012723-bbs2-0079" title="SmithPC . Management of reticular veins and telangiectases. Phlebology2015;30(2 Suppl):46-52. [PMID: 26556703]">Smith 2015</a> studied the management of reticular veins and telangiectasias of the lower limb, by sclerotherapy, radiofrequency and laser. They concluded that sclerotherapy was the most effective method for the treatment of reticular veins and telangiectasias. This was a narrative rather than a systematic review, and included all types of studies. </p> <p>In the Management of Chronic Venous Disease Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS), <a href="./references#CD012723-bbs2-0086" title="WittensC , DaviesAH , BaekgaardN , BroholmR , CavezziA , ChastanetS , et al. Editor's Choice - Management of Chronic Venous Disease: Clinical Practice Guidelines of the European Society for Vascular Surgery (ESVS). European Journal of Vascular and Endovascular Surgery2015;49(6):678-737. [PMID: 25920631]">Wittens 2015</a> recommended that liquid sclerotherapy should be considered for treating telangiectasias and reticular veins. This recommendation was made based on studies that were included in our review (<a href="./references#CD012723-bbs2-0012" title="KahleB , LengK . Efficiency of sclerotherapy of spider leg veins. A prospective, randomized, double-blind, placebo-controlled study. Vasomed2006;18:148. ">Kahle 2006</a>, <a href="./references#CD012723-bbs2-0032" title="RabeE , SchliephakeD , OttoJ , BreuFX , PannierF . Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology2010;25(3):124-31. [PMID: 20483861]">Rabe 2010</a>, <a href="./references#CD012723-bbs2-0035" title="ZhangJ , JingZ , SchliephakeDE , OttoJ , MaloufGM , GuYQ . Efficacy and safety of Aethoxysklerol (R) (polidocanol) 0.5%, 1% and 3% in comparison with placebo solution for the treatment of varicose veins of the lower extremities in Chinese patients (ESA-China Study). Phlebology2012;27(4):184-90. [PMID: 22045827]">Zhang 2012</a>). European guidelines for sclerotherapy in chronic venous disorders (<a href="./references#CD012723-bbs2-0070" title="RabeE , BreuFX , CavezziA , Coleridge SmithP , FrulliniA , GilletJL , et al. European guidelines for sclerotherapy in chronic venous disorders. Phlebology2014;29(6):338-54. [PMID: 23559590]">Rabe 2014</a>) also recommends sclerotherapy as a treatment for telangiectasias. </p> <p><a href="./references#CD012723-bbs2-0088" title="YiannakopoulouE . Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology2016;98(1-2):62-9. [PMID: 27104778]">Yiannakopoulou 2016</a> studied the adverse events of sclerosing agents. Hyperpigmentation and matting were the most frequently‐reported local adverse events in sclerotherapy, a finding supported by our review. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012723-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD012723-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies." data-id="CD012723-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD012723-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sclerotherapy (any sclerosing agent) versus placebo, Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Sclerotherapy (any sclerosing agent) versus placebo, Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sclerotherapy (any sclerosing agent) versus placebo, Outcome 2: Adverse events" data-id="CD012723-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Sclerotherapy (any sclerosing agent) versus placebo, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Sclerotherapy (any sclerosing agent) versus placebo, Outcome 3: Pain" data-id="CD012723-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Sclerotherapy (any sclerosing agent) versus placebo, Outcome 3: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events" data-id="CD012723-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain" data-id="CD012723-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events" data-id="CD012723-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain" data-id="CD012723-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events" data-id="CD012723-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain" data-id="CD012723-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-005.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-005.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-005.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-005.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-005.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events" data-id="CD012723-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-005.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-005.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-005.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-005.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 5: Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain" data-id="CD012723-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-005.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-005.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5: Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent), Outcome 3: Pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-005.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-006.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Foam versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-006.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-006.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6: Foam versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-006.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-006.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Foam versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events" data-id="CD012723-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-006.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-006.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6: Foam versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-006.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-006.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 6: Foam versus sclerotherapy (any sclerosing agent), Outcome 3: Pain" data-id="CD012723-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-006.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-006.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6: Foam versus sclerotherapy (any sclerosing agent), Outcome 3: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-006.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-007.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Laser versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-007.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-007.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7: Laser versus sclerotherapy (any sclerosing agent), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-007.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-007.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Laser versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events" data-id="CD012723-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-007.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-007.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7: Laser versus sclerotherapy (any sclerosing agent), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-007.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-007.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 7: Laser versus sclerotherapy (any sclerosing agent), Outcome 3: Pain" data-id="CD012723-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-007.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-007.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.3</div> <div class="figure-caption"> <p>Comparison 7: Laser versus sclerotherapy (any sclerosing agent), Outcome 3: Pain</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-007.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-008.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-008.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-008.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8: Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-008.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-008.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol), Outcome 2: Adverse events" data-id="CD012723-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-008.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-008.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.2</div> <div class="figure-caption"> <p>Comparison 8: Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-008.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-008.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 8: Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol), Outcome 3: Pain" data-id="CD012723-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-008.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-008.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.3</div> <div class="figure-caption"> <p>Comparison 8: Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol), Outcome 3: Pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-008.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-009.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose), Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-009.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-009.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9: Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose), Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-009.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-009.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose), Outcome 2: Adverse events" data-id="CD012723-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-009.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-009.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9: Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose), Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-009.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-009.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 9: Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose), Outcome 3: Pain" data-id="CD012723-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-009.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-009.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.3</div> <div class="figure-caption"> <p>Comparison 9: Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose), Outcome 3: Pain </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-009.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-010.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sclerotherapy plus compression versus sclerotherapy alone, Outcome 1: Resolution or improvement of telangiectasias" data-id="CD012723-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-010.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-010.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10: Sclerotherapy plus compression versus sclerotherapy alone, Outcome 1: Resolution or improvement of telangiectasias </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-010.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-010.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sclerotherapy plus compression versus sclerotherapy alone, Outcome 2: Adverse events" data-id="CD012723-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-010.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-010.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10: Sclerotherapy plus compression versus sclerotherapy alone, Outcome 2: Adverse events </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-010.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012723-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/urn:x-wiley:14651858:media:CD012723:CD012723-CMP-010.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 10: Sclerotherapy plus compression versus sclerotherapy alone, Outcome 3: Quality of life" data-id="CD012723-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-010.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_t/tCD012723-CMP-010.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10: Sclerotherapy plus compression versus sclerotherapy alone, Outcome 3: Quality of life </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/media/CDSR/CD012723/image_n/nCD012723-CMP-010.03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (any)<br/><b>Comparison:</b> placebo </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures*<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with placebo</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 3.08 higher<br/>(2.68 higher to 3.48 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>613<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 11.88<br/>(4.54 to 31.09) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>528<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>25 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>299 per 1000<br/>(114 to 784) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 4.06<br/>(1.28 to 12.84) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>528<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>17 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>68 per 1000<br/>(22 to 216) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.7 higher<br/>(0.06 higher to 1.34 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Three studies used participants as the unit of analysis and one study used the number of procedures as the unit of analysis for each comparison. <br/><sup>a</sup>We downgraded by one level due to high clinical heterogeneity of the included studies.<br/><sup>b</sup>We downgraded by one level due to high clinical heterogeneity of the included studies and wide CI of the included studies (imprecision).<br/><sup>c</sup> We downgraded by two levels due to high clinical heterogeneity of the included studies and only one included study with few participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Sclerotherapy compared to placebo for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (polidocanol)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosant agent)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (polidocanol)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.01 higher<br/>(0.13 lower to 0.14 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>852<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.94<br/>(0.62 to 1.43) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>819<br/>(6 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>476 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>447 per 1000<br/>(295 to 680) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.82<br/>(0.52 to 1.27) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>859<br/>(7 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>144 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>118 per 1000<br/>(75 to 183) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.26 lower<br/>(0.44 lower to 0.08 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>480<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Three studies used participants as the unit of analysis and four studies used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by one level due to wide CIs. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Sclerotherapy (polidocanol) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (STS)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosant)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (STS)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.07 lower<br/>(0.25 lower to 0.11 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>473<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.71<br/>(1.10 to 2.64) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>478<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>371 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>634 per 1000<br/>(408 to 979) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.10<br/>(1.14 to 3.85) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>323<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>82 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>173 per 1000<br/>(94 to 318) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.49<br/>(0.99 to 2.25) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>409<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>275 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>410 per 1000<br/>(273 to 619) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Two studies used participants as the unit of analysis and four studies used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by one level due to wide CIs and small number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Sclerotherapy (STS) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0004"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (hypertonic saline)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosant)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (hypertonic saline)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.01 higher<br/>(0.2 lower to 0.22 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 8 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.74<br/>(0.59 to 0.93) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>493 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>365 per 1000<br/>(291 to 459) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 8 ‐ 12 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.89<br/>(0.58 to 1.36) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>288<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>215 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>192 per 1000<br/>(125 to 293) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 6.22 higher<br/>(5.7 higher to 6.73 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>348<br/>(3 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD</b>: standard mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> All studies used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by one level because of high risk of other bias in the included studies.<br/><sup>b</sup>We downgraded by one level because of wide CIs.<br/><sup>c</sup>We downgraded by one level because of clinical heterogeneity between included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 4.</span> <span class="table-title">Sclerotherapy (hypertonic saline) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0005"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy (chromated glycerin)<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosing agent)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (chromated glycerin)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 5 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.45 higher<br/>(0.11 lower to 1.02 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 5 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.49<br/>(0.09 to 2.50) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>125<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>66 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>32 per 1000<br/>(6 to 164) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 5 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.31<br/>(0.01 to 7.53) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>99<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>21 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>6 per 1000<br/>(0 to 157) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.50</p> <p>(0.30 to 7.55)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>26<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>154 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>231 per 1000<br/>(46 to 1000) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> One study used participants as the unit of analysis and one study used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup> We downgraded by two levels due to few included studies and participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 5.</span> <span class="table-title">Sclerotherapy (chromated glycerin) compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0006"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Foam compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Foam compared to sclerotherapy (any sclerosant) for telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> foam<br/><b>Comparison:</b> sclerotherapy (any sclerosant) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy (any sclerosing agent)</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with foam</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 5 ‐ 10 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.04 higher<br/>(0.26 lower to 0.34 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 5 ‐ 10 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.12<br/>(0.44 to 10.23) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>26 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>55 per 1000<br/>(11 to 265) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow up: 5 ‐ 10 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 6.12<br/>(1.04 to 35.98) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>187<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝</p> <p>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>9 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(9 to 310) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain</b> </p> <p>(follow up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.1 lower<br/>(0.44 lower to 0.24 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> One study used participants as the unit of analysis and one study used the number of procedures as the unit of analysis for each comparison.<br/><sup>a</sup>We downgraded by two levels due to wide CIs and few participants in the included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 6.</span> <span class="table-title">Foam compared to sclerotherapy (any sclerosant) for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0007"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser<br/><b>Comparison:</b> sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with laser</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.09 lower<br/>(0.25 lower to 0.07 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>593<br/>(5 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ hyperpigmentation </p> <p>(follow‐up: 4 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.57<br/>(0.40 to 0.80) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>262<br/>(4 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>328 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>187 per 1000<br/>(131 to 263) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 16 ‐ 24 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.00<br/>(0.46 to 2.19) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>162<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>123 per 1000<br/>(57 to 270) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>100<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊝⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>We were not able to pool the data due to high heterogeneity</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> Two studies used participants as the unit of analysis and three studies used the number of procedures as the unit of analysis for each comparison </p> <p><sup>a</sup>We downgraded by one level due to wide CIs.<br/><sup>b</sup>We downgraded by two levels because of few included participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 7.</span> <span class="table-title">Laser compared to sclerotherapy for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0008"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> laser plus sclerotherapy<br/><b>Comparison:</b> sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants/procedures<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with laser plus sclerotherapy</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 5.68 higher<br/>(5.14 higher to 6.23 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>710<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ Hyperpigmentation </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.35 to 1.99) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>64 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>53 per 1000<br/>(22 to 128) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events</b> ‐ matting </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.83<br/>(0.21 to 3.28) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>656<br/>(2 RCTs) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>18 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>15 per 1000<br/>(4 to 60) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 1 day)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 2.44<br/>(1.69 to 3.55) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>596<br/>(1 RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>266 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>649 per 1000<br/>(449 to 944) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> All studies used participants as the unit of analysis.<br/><sup>a</sup>We downgraded by two levels because of clinical heterogeneity in the included studies and the fact that the two studies were conducted by the same group of investigators.<br/><sup>b</sup>We downgraded by two levels due to having one included study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 8.</span> <span class="table-title">Laser plus sclerotherapy compared to sclerotherapy for treatment of telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0009"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sclerotherapy (hypertonic glucose plus polidocanol) compared to sclerotherapy (hypertonic glucose)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Sclerotherapy (hypertonic glucose plus polidocanol) compared with sclerotherapy (hypertonic glucose) for telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> people with telangiectasias and reticular veins </p> <p><b>Settings:</b> outpatient </p> <p><b>Intervention:</b> sclerotherapy (hypertonic glucose plus POL) </p> <p><b>Comparison:</b> sclerotherapy (hypertonic glucose) </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>No of Participants<sup>*</sup><br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with hypertonic glucose</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with hypertonic glucose plus POL</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 12 ‐ 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.79 higher</p> <p>(0.50 higher to 1.09 higher)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> hyperpigmentation </p> <p>(follow‐up: 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.79</p> <p>(0.62 to 1.01)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>649 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>513 per 1000<br/>(403 to 656) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> matting </p> <p>(follow‐up: 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.78</p> <p>(0.51 to 1.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝<br/>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>351 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>273 per 1000<br/>(179 to 421) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Pain</b> </p> <p>(follow‐up: 16 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.02</p> <p>(0.83 to 1.24)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>191</p> <p>(2 RCTs)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>443 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>442 per 1000</p> <p>(359 to 537)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Quality of life</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>POL</b> : polidocanol; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD:</b> standardised mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup> All studies used participants as the unit of analysis.<br/><sup>a</sup>We downgraded one level because of few participants in included studies. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 9.</span> <span class="table-title">Sclerotherapy (hypertonic glucose plus polidocanol) compared to sclerotherapy (hypertonic glucose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD012723-tbl-0010"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> people with telangiectasias and reticular veins<br/><b>Setting:</b> outpatient<br/><b>Intervention:</b> sclerotherapy plus compression<br/><b>Comparison:</b> sclerotherapy </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>№ of participants<br/>(studies)<sup>*</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Risk with sclerotherapy plus compression</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Resolution or improvement of telangiectasias</b> </p> <p>(follow‐up: 4 ‐ 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.09 higher<br/>(0.19 lower to 0.37 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> hyperpigmentation </p> <p>(follow‐up:4 ‐ 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 0.93<br/>(0.41 to 2.07) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>196<br/>(2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊕⊝</p> <p>MODERATE<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>112 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>104 per 1000<br/>(46 to 232) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Adverse events ‐</b> matting </p> <p>(follow‐up: 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>RR 1.84<br/>(0.17 to 19.62) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>96<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>22 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>40 per 1000<br/>(4 to 427) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pain</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Recurrence</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Time to resolution</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>See comment</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The studies in this comparison did not assess this outcome</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Quality of life</b> </p> <p>(follow up: 8 weeks)</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"></td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>SMD 0.02 lower<br/>(0.42 lower to 0.39 higher) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/>LOW<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>RCT:</b> randomised controlled trial; <b>RR:</b> risk ratio; <b>SMD</b>: standard mean difference </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE Working Group grades of evidence</b> <br/><b>High certainty:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate certainty:</b> We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/><b>Low certainty:</b> Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect<br/><b>Very low certainty:</b> We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>*</sup>All studies used participants as the unit of analysis.<br/><sup>a</sup>We downgraded one level because of few participants in included studies.<br/><sup>b</sup>We downgraded two levels because of few participants and only one included study. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 10.</span> <span class="table-title">Sclerotherapy plus compression compared to sclerotherapy alone for telangiectasias and reticular veins</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/full#CD012723-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sclerotherapy (any sclerosing agent) versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>613</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.08 [2.68, 3.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>11.88 [4.54, 31.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>528</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.06 [1.28, 12.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Sclerotherapy (any sclerosing agent) versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.13, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>819</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.94 [0.62, 1.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>859</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.52, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.3 Bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.77 [0.56, 1.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.4 Microthrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>394</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.69, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.5 Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>472</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.23, 2.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.6 Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>558</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [0.02, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>480</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.44, ‐0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Sclerotherapy (polidocanol) versus sclerotherapy (any sclerosing agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.25, 0.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>478</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.71 [1.10, 2.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>323</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.10 [1.14, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.3 Bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>418</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.62 [1.14, 2.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.4 Microthrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.78, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.5 Allergy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>452</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.38 [1.01, 1.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2.6 Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>392</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>16.31 [3.14, 84.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>409</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.49 [0.99, 2.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Sclerotherapy (STS) versus sclerotherapy (any sclerosing agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.20, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.59, 0.93]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>288</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.58, 1.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>348</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.22 [5.70, 6.73]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sclerotherapy (hypertonic saline) versus sclerotherapy (any sclerosing agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [‐0.11, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>125</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.09, 2.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.01, 7.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.3 Bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>26</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.14 [0.02, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2.4 Microthrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.45, 3.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Sclerotherapy (chromated glycerin) versus sclerotherapy (any sclerosing agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Foam versus sclerotherapy (any sclerosing agent)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.26, 0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [0.44, 10.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>6.12 [1.04, 35.98]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.3 Bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.60 [0.35, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2.4 Microthrombosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.39 [0.70, 2.76]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Foam versus sclerotherapy (any sclerosing agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Laser versus sclerotherapy (any sclerosing agent)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>593</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.09 [‐0.25, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>262</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.57 [0.40, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.46, 2.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.3 Bruising</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.60, 1.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2.4 Necrosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.60 [0.20, 12.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Laser versus sclerotherapy (any sclerosing agent)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>710</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.68 [5.14, 6.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.35, 1.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>656</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.83 [0.21, 3.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Laser plus sclerotherapy (polidocanol) versus sclerotherapy (polidocanol)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.50, 1.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.79 [0.62, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.51, 1.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9.3 Pain <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>191</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.83, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sclerotherapy (polidocanol plus glucose) versus sclerotherapy (glucose)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012723-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sclerotherapy plus compression versus sclerotherapy alone</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.1 Resolution or improvement of telangiectasias <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.19, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.2 Adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.1 Hyperpigmentation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>196</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.41, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.2.2 Matting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>96</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [0.17, 19.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10.3 Quality of life <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sclerotherapy plus compression versus sclerotherapy alone</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012723.pub2/references#CD012723-tbl-0020">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012723.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD012723-note-0021">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012723-note-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012723-note-0019">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD012723-note-0017">Hrvatski</a> </li> <li class="section-language"> <a class="" href="hu#CD012723-note-0020">Magyar</a> </li> <li class="section-language"> <a class="" href="ms#CD012723-note-0016">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012723-note-0014">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012723-note-0015">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012723\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012723\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012723\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012723\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012723\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012723.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012723.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012723.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012723.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012723.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725567856"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012723.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725567859"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012723.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e7e644e12f466',t:'MTc0MDcyNTU2OC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 